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1. The endocannabinoid system 
The past decade has seen a sudden spurt of interest in the endocannabinoid system 
(ECs). This system regulates a plethora of biological effects and is composed of 
cannabinoid and vanilloid receptors, endogenous signaling molecules (called 
endocannabinoids) and metabolism-related enzymes! (De Petrocellis et al, 2000; Di et 
al, 2000). Endocannabinoids are a class of lipid mediators found in several tissues and 
based on a polyunsaturated fatty acid amide or ester motifs! (Di Marzo et al, 2002). 
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the most characterized 
endocannabinoids acting in the brain and in peripheral tissues mainly through the 
activation CB1 and CB2 cannabinoid receptors, respectively. AEA can also interact with 
the vanilloid receptor type 1 TRPV1 (Smart et al, 2000; Zygmunt et al, 1999). This non-
selective cation channel is activated by vanilloids, such as capsaicin, and also by 
endogenous ligands N-acyl-dopamines (neurolipins), such as N-arachidonoyl-
dopamine (NADA) and N-oleoyl-dopamine (OLDA) (Caterina et al, 1997; Chu et al, 
2003; Huang et al, 2002). 
 
2. N-arachidonoyl-dopamine, NADA 
 While NADA binds TPRV1 (Huang et al, 2002; Toth et al, 2003), and CB1 
receptor and induces several biological activities such as hyperalgesia (Chu et al, 
2003), smooth muscle contraction in the guinea pig bronchi and bladder (Harrison et al, 
2003), vasorelaxation in blood vessels (O'Sullivan et al, 2004), and also has 
immunomodulatory, neuroprotective and antiinflammatory properties (Bobrov et al, 
2008; Navarrete et al, 2009; Sancho et al, 2004). Their saturated analogs N-palmitoyl-
dopamine (PALDA) and N-stearoyl-dopamine (STEARDA) were also identified as 
endogenous substances not activating TRPV1, although they significantly enhanced 
the TRPV1-mediated effects of NADA (Chu et al, 2003). 
Endocannabinoids may play a major role in the central nervous system (CNS), 
immune control and neuroprotection by regulating the cellular network of 
communication between the nervous and immune system during neuroinflammation 
and neuronal damage (Achiron et al, 2000; Malfitano et al, 2006; Pryce et al, 2003). In 
addition, N-acyl-dopamines influence the lipoxygenase pathway of arachidonic acid 
cascade as substrates or inhibitors and may also be involved in the regulation of 
inflammation (Bezuglov et al, 1997; Tseng et al, 1992). 
Introduction 
!
3 
3. The Cyclooxygenase catalysis 
Cyclooxygenases catalyse the first step in the synthesis of prostanoids, a large 
family of arachidonic acid metabolites, including prostaglandins (PGs), prostacyclins 
and thromboxanes. The inducible isoform COX-2 is involved in the mediation of 
inflammation, immunomodulation, blood flow, apoptosis and fever (Cao et al, 2001; 
Dubois et al, 1998). COX-2 is rapidly expressed on several cell types in response to 
growth factors, proinflammatory molecules and cytokines (Caughey et al, 2001; 
Moolwaney & Igwe, 2005). Proinflammatory cytokines such as IL-1β and TNF-α 
increase the expression of COX-2 in brain microvessel endothelial cells and this has 
been related to increases in permeability of the cerebral microvasculature (Cao et al, 
2001; Mark et al, 2001). The production of several PGs, secondary to induction of 
COX-2, by the cells lining the blood–brain barrier (BBB), which may diffuse to the brain 
parenchyma, may have important consequences in brain inflammatory processes by 
modulating blood flow and also the intracerebral immune responses. 
We were interested in studying the effect of NADA on key MAP kinases on 
genome stability (i.e. p38 MAPK) as well as on other regulators of immflamatory 
processes and tumorigenesis (i.e. COX-2, SIAH2). In this dissertation we have also 
studied very in detail how SIAH2 phosphorylation by DYRK2 (another important kinase 
in genome stability) influences tumorigenesis and the outcomes of DYRK2 degradation 
by SIAH2 on cell apoptosis pathways. 
 
4. Genomic instability in cancer 
 To maintain genome integrity and fidelity, cells present complex signaling 
networks that are activated when genomic material is damaged as a consequence of 
exposition to oncogenic stress. The failure or loss of functionality of some of these 
control systems largely threatens the viability of the organism, thereby causing 
cytotoxicity, blocks in the correct DNA transcription and replication and, eventually, 
mutagenesis.  
 Genetic instability can be defined as a number of events capable of causing a 
wide number of unscheduled alterations that can be easily classified as single 
nucleotide mutations and chromosomal instabilities (Charames & Bapat, 2003). Along 
the same line, genomic instability is also due to chromosomal double-strand DNA 
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breaks (DSBs) that occur after exposure to ionizing radiation, after the collapse of 
replication forks when replication blocks at DNA intra-strand cross-links brought about 
by UV light or after chemotherapeutical agents (Hoeijmakers, 2001). 
 The DNA damage response network involves a number of pathways such as 
the PI3-kinase/AKT, Iκκ/NFκB and various MAP Kinases (MAPKs)(Huang et al, 2003; 
Kyriakis & Avruch, 2001; Saleem et al, 1995). These pathways start as response to 
number of events occurs at the DSB region in the DNA. First of all, a mediator complex 
consisting of Mre11, Rad50 and Nbs1 (MRN) is recruited and phosphorylation of a 
variant H2A histone (H2AX) takes place (Fernandez-Capetillo et al, 2004). This serves 
to intensify the signal and recruit new molecules to the DSB lesion, where finally the 
ATM (ataxia-telangiectasia) and ATR (ATM- and Rad3- Related) signaling pathways 
come into play (Falck et al, 2005).  
 ATM and ATR signaling pathways orchestrate downstream effectors by 
targeting them with phosphate residues (Figure 1). Once active ATM phosphorylates 
p53 on serine 15 and CHK2 on threonine 68 that likewise phosphorylates p53, but on 
serine 20 instead (Khosravi et al, 1999). Once p53 is phosphorylated on those two 
residues it escapes from Mdm2-dependent proteasomal degradation and act as an 
active transcription factor. ATM directly interferes with p53-Mdm2 interaction by 
phosphorylating Mdm2 on serine 395 (Maya et al, 2001).  
 Besides ruling p53-CHK2-Mdm2 axis, ATM regulates many other important 
substrates. It phosphorylates the tumor-suppressor protein BRCA1 on serines 1387 
and 1423 following DNA damage (Cortez et al, 1999; Gatei et al, 2001). It also inhibits 
CtIP which is an inhibitor of BRCA1. In this regard, CHK2, previously activated by ATM, 
likewise phosphorylates and activates BRCA1. Other important ATM targets in the DSB 
response are NBS1, SIAH-1 and DYRK2 (Lim et al, 2000; Taira et al; Winter et al, 
2008). Furthermore, CHK1 is activated by ATR on serines 315 and 345 by means of 
the mediator protein claspin (Kumagai et al, 2004; Zhao & Piwnica-Worms, 2001). Both 
CHKs proteins converge to inactivate members of the Cdc25 family of dual-specificity 
phosphatases, responsible for ruling cell cycle divisions (Donzelli & Draetta, 2003). 
However, while the ATM/Chk2 pathway is primarily involved in DNA double-strand 
breaks, the ATR-Chk1 pathway is mainly required for replication-associated DNA 
lesions (Bartek & Lukas, 2003; Pommier et al, 2006). 
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Figure 1. Important signaling pathways involved in cell cycle regulation 
 
 As well as the regulations mentioned straightforwardly above that end up 
activating cell-cycle checkpoints, further modifications of p53 enhance such responses 
driving the cell to apoptosis (Oda et al, 2000). In this respect, it has been reported 
since 2002 that ATM, DNA-PK, PKCδ, DYRK2 and HIPK2 phosphorylate p53 on serine 
46 (D'Orazi et al, 2002; Komiyama et al, 2004; Saito et al, 2002; Taira et al, 2007; 
Yoshida et al, 2006). HIPK2-dependent p53 regulation has been is extensively and 
thoroughly reported ever since, and not so much about the DYRK2-p53 axis which first 
came to light in 2007. As regards HIPK2 regulation over p53 it is worth pointing out o 
number of findings. Once HIPK2 phosphorylates p53 at Ser 46, it stimulates CBP-
mediated p53 acetylation at Lys 382 (D'Orazi et al, 2002; Hofmann et al, 2002; Puca et 
al, 2009).  
 Among HIPK2 upstream control proteins we should have a close look at the role 
of both SIAH-1 and SIAH-2. Under DBS lesions, ATM phosphorylates SIAH-1 on serine 
19 which disrupts its binding with HIPK2, whereupon it locates to the nucleus and 
targets p53 for phosphorylation on serine 46 (Figure 1). In addition, ATM hinders 
MDM2 levels making HIPK2 unavailable for degradation. Under hypoxia events WSB-
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1, SIAH-1L, SIAH1 and SIAH2 downregulate HIPK2 levels, and thus inactivate the p53 
apoptotic response. Under these circumstances, HIF-1α levels increase high enough to 
restrain HIPK2 accumulation. Likewise HIPK2 rescue from MDM2-dependent 
degradation by ATM, DYRK2 interaction with MDM2 is inhibited once the kinase is 
phosphorylated by ATM. Once this happens, DYRK2 phosphorylates p53 on serine 46 
and the apoptotic response finally takes place (Figure 2).  
 
Figure 2. Balance outcome when either DNA damage or hypoxia takes place. 
 
5. Protein kinase signaling networks in cancer 
Protein kinases are enzymes able that phosphorylate precise tyrosine, serine or 
threonine residues on other kinases or other substrates so as to spread signals from 
extra- and intracellular stimuli. They rule many signaling pathways to control important 
physiological processes such as cell survival, proliferation and cell growth. Both the 
vast number of kinases, 539, encoded by the genome and the abundance of 
phosphorylation sites reported so far explain how mutations or abnormal protein 
expression may lead to many diseases such as rheumatoid arthritis, cardiovascular 
and neurological disorders, asthma, psoriasis and cancer. While some mutations 
enhance the protein catalytic activity of the proteins (such as PI3KCA), other mutations 
reduce their activity (c-FES and MAP2K4). More than 400 diseases have been related 
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so far to an impairment of kinases roles (Brognard & Hunter; Melnikova & Golden, 
2004). So much so, that a number of signaling pathways controlled by kinases have 
been reported to be tied up with transformations processes: the cytoplasmic (Ras-Raf-
MEK-ERK)-, the Wnt/β-catenin-, Hedgehog-, the JAK/STAT-, PI3K/PKB- and the Notch 
pathway (Rennefahrt et al, 2005). 
As the literature reports, kinase activity can be controlled by different 
mechaninsms: blocking ATP binding so as to inhibit the catalytic activity, hampering 
protein interactions, knocking down by antisense or RNA interference approaches 
genes encoding kinases (Melnikova & Golden, 2004), etc. Thus, further knowledge of 
kinases control mechanisms urges to be brought to light. In this respect we have come 
upon a compelling and far-reaching regulation of a kinase reported to drive the cell to 
apoptosis under genotoxic stress. 
 
6. DYRK 
Dual-specificity tyrosine-regulated kinases (DYRKs) belong to the CMGC group, 
which also includes cyclin-dependent kinases (CDKs), mitogen-activated protein 
kinases (MAPKs), glycogen synthase kinase-3 (GSK3), CDK-like kinases, 
serine/arginine-rich protein kinases, cdc2-like kinases, and RCK kinases. The DYRK 
family is divided in turn into three subfamilies: DYRK kinases, homeodomain-interacting 
protein kinases (HIPKs), and pre-mRNA processing protein 4 kinases (PRP4s). Two 
members of the family have been reported in Caenorhabditis elegans (MBK-1 and 
MBK-2), whereas 3 members exist in Drosophila melanogaster (minibrain, dDyrk2, and 
dDyrk3). As respect to mammals, DYRKs comprise DYRK1A, DYRK1B (or MIRK), 
DYRK2, DYRK3 (or REDK), and DYRK4 (Figure 3)(Aranda et al; Becker et al, 1998). 
DYRKs autophosphorylate on tyrosine residues so as to become active and 
phosphorylate on serine/threonine residues on exogenous substrates (Becker & Joost, 
1999; Campbell & Proud, 2002; Himpel et al, 2001; Li et al, 2002a; Lochhead et al, 
2003). Likewise the TXY motif that MAPKs (mitogen-activated protein kinases) have to 
phosphorylate their substrates, DYRKs have an YXY sequence in the activation loop of 
their catalytic domain (Kentrup et al, 1996). This fact suggests that DYRKs proteins 
could be involved in very similar pathways as the MAPKs are (Miyata & Nishida, 1999). 
The five members in mammals share a kinase domain as well as a sequence just 
upstream of the kinase domain named the DYRK homology (DH)-box which is 
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characteristic of the subfamily in question. Besides, the paralogous pair DYRK1A-
DYRK1B shares a NLS (nuclear localization Signal) and a PEST (motif rich in proline, 
glutamic acid, serine, and threonine residues) domain. The other three members have 
a NAPA (N-terminal autophosphorylation accessory region) domain that provides a 
chaperone-like function for the intermediate form with tyrosine autophosphorylation 
activity. 
 
 
Figure 3. The 5 mammalian DYRKs structure. Yellow squares represent polyhistidene 
stretch. Brown squares represent regions enriched in Ser and Thr residues. 
 
DYRK1A is the founding member of this family, is the best well known among 
the rest isotypes and maps to the DSCR (Down Syndrome Critical Region) of 
chromosome 21 (Guimera et al, 1996; Shindoh et al, 1996; Song et al, 1996). Besides 
being involved in neurological disorders such as Down syndrome, it is also implicated 
in calcium signaling by phosphorylating NFAT (Gwack et al, 2006) and cell polarity 
maintenance in Schizosaccharomyces pombe (Tatebe et al, 2005). Furthermore it is 
embroiled in various biochemical pathways as it is able to phosphorylate many other 
substrates such as: STAT3 (Matsuo et al, 2001), eIF2B and Tau (Woods et al, 2001) 
(Aranda et al). As concerns DYRK1B, it mediates cell survival and differentiation and is 
highly expressed in muscle tissues (Lee et al, 2000; Mercer et al, 2005; Mercer & 
Friedman, 2006). It has been reported to phosphorylate among other substrates: 
p21Cip1 (Zhou et al, 2001) and class II HDACs (Deng et al, 2005) (Aranda et al). 
As it is reported further on in this dissertation, DYRK2 is the isoform we report 
as a new protein of interest in the response to hypoxia and gentoxic stress. DYRK2 is 
involved in regulating key developmental and cellular processes such as neurogenesis, 
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cell proliferation, cytokinesis, and cellular differentiation. A wide number of substrates 
have been reported to be phosphorylated by DYRK2. Some of these are: Katanin p60!
(Maddika & Chen, 2009), NFAT! (Gwack et al, 2006), p53! (Taira et al, 2007), Stat3!
(Matsuo et al, 2001), Tau! (Woods et al, 2001), and very recently c-Jun and c-Myc 
(Taira et al)! (Aranda et al). A number of publications relate DYRK2 to an adequate 
prognosis (Yamashita et al, 2009) (Taira et al) and also as responsible for the 
regulation of tumour progression via c-Jun and c-Myc. 
As it was mentioned above, in 2007 a finding of great importance shed light a 
major role of DYRK2 as concern the regulation of cell physiology upon DNA damage 
(Taira et al, 2007). Since then many publications have brought into light the importance 
of getting to know the regulation of DYRK2 in a comprehensive, accurate and 
exhaustive way. In this dissertation we would like to put forward a new molecular 
mechanism whereby DYRK2 is ruled under hypoxia events by the ubiquitin ligase 
SIAH2. Under these circumstances we have seen how p53 regulation is altered both at 
a protein and at a transcriptional level. Nevertheless, we describe SIAH2 as a new and 
direct substrate of DYRK2 whose activity is enhanced over some substrates (i.e. 
PHD3) by a DYRK2-phosphorylation dependent manner. 
DYRK3 is highly produced in hematopoietic cells and testis. It reduces 
apoptosis in response to cytokine starvation in hematopoietic cells (Geiger et al, 2001) 
and has been reported to phosphorylate SIRT1 (Guo et al), myelin basic protein and 
histones H2b and H3 (Lord et al, 2000). DYRK4 is the least known isoform of all the 
DYRK family members. It is exclusively expressed in the testis and helps the process 
of spermiogenesis (Sacher et al, 2007).As regards DYRK subcellular localization, 
DYRK1A and DYRK1B contain a NLS domain that confers them nuclear localization. 
Concerning DYRK2, it has been reported a cytoplasmic localization under normal 
conditions (Becker et al, 1998; Leder et al, 1999) that following genotoxic stress moves 
into the nucleus (Taira et al, 2007). This nuclear accumulation depends on an NLS in 
the N terminus of the protein and on an Mdm2-dependent increase in protein stability 
(Taira et al). Despite the absence of NLS domain on DYRK3, it shows nuclear 
localization (Lord et al, 2000). Finally, as regards DYRK4 localization it has not been 
clarified so far. 
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7. SIAH (seven in absentia homolog) 
The SIAH (seven in absentia homolog) protein family belongs to the RING 
finger E3 ubiquitin ligases family, which are involved in ubiquitination and proteasome-
mediated degradation of specific substrates (Lorick et al, 1999; Schnell & Hicke, 2003; 
Tang et al, 1997). The first member of this highly homologue family was initially 
identified in Drosophila melanogaster as seven in absentia (sina), a protein needed for 
photoreceptor R7 formation (Carthew et al, 1994; Li et al, 1997). Other three genes 
were later identified in mice (Siah1a, Siah1b and Siah2)(Della et al, 1993; Holloway et 
al, 1997). The human SIAH family consists of two proteins (SIAH1 and SIAH2) from 
different genes, which perform different but in some cases, redundant functions (Hu et 
al, 1997a). 
 
Figure 4. SIAH2 full sequence showing the three basic domains: RING, Zinc Fingers and SBD. 
 
Human SIAH2 is a 324 amino acid dimeric protein presenting a RING (Real 
Interesting New Gen) catalytic domain in its N-terminal that recruits E2 ubiquitin-
conjugating enzymes, two zinc-finger motifs and a substrate-binding domain (SDB) in 
its C-terminal (House et al, 2006; Polekhina et al, 2002)(Figure 4). SIAH2 may exert its 
activity as ubiquitin ligase E3 either through its binding to adapting proteins such as 
phyllopod (PHYL) and Siah-interacting protein (SIP)(Li et al, 2002b; Matsuzawa & 
Reed, 2001) or through direct interaction to the substrate protein (Calzado et al, 2009b; 
Roysarkar et al). A wide number of SIAH2 substrates implied in the regulation of 
important signalling pathways have been described (Nakayama et al, 2009). These 
are: PML (Promyelocytic leukemia protein)(Fanelli et al, 2004), PHD (prolyl 
hydroxylases)(Nakayama et al, 2004), Sprouty (Nadeau et al, 2007), TRAF2 (receptor-
associated factor 2)(Habelhah et al, 2002), DCC (Hu et al, 1997b), β-catenin (Topol et 
al, 2003), N-CoR (Zhang et al, 1998), HIPK2 (Calzado et al, 2009b), PPARγ (Kilroy et 
al), OGDHC-E2 (2-oxoglutarate dehydrogenase complex)(Habelhah et al, 2004), TIN2 
(Bhanot & Smith), HDAC3 (Zhao et al), AKAP121 (Carlucci et al, 2008) and α-synuclein 
(Liani et al, 2004). Siah2 knock-out mice show faint phenotypes, such as fewer 
1" 324"
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amounts of hematopoietic progenitor cells. In contrast, Siah1a and Siah2 double knock-
out mice are embryonic lethal, denoting an key purpose in embryogenesis and putting 
forward that the two Siah homologs have both overlapping and distinct rolls in vivo 
(Frew et al, 2003). 
As it was said above, SIAH2 degrades specific substrates by means of its 
ubiquitin ligase activity. Ubiquitination consists of attaching minor proteins to the target 
protein of interest driving it to either attenuating its function or putting them on a spurt. 
That appurtenance is called ubiquitin. This protein, lacking in archaeal or eubacterial, 
attaches covalently to those proteins that are going to get rid of by proteolysis. Also, 
non degrading reasons have been ascribed to ubiquitins (Hochstrasser, 2000). The 
process of ubiquitination consists of three consecutive steps that involves three 
different enzymes (Figure 5). The first step comprise the activation of ubiquitin using 
ATP by the use of E1 activating enzyme, the second steps involves a second protein, 
called E2 conjugating enzyme that, by means of a thioester bond, transfers the 
activated ubiquitin from E1 to E3, which is the last enzyme used in this process. The E3 
ligase enzyme ties the activated ubiquitin to the ε-amino group of a lysine residue in a 
specific substrate (Hershko & Ciechanover, 1998). 
 
Figure 5. Ubiquitin conjugation scheme that depicts a straightforward representation of how 
ubiquitin enzymes work. 
Whereas not many E1 activating enzymes have been described, more than 20 
different E2 conjugating enzymes have been reported in humans. In contrast, among 
500 to 1000 different E3 ligase enzymes are present in humans (Hicke et al, 2005). E3 
enzymes are classified in two leading groups: RING (really interesting new gene) and 
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HECT (homologous to the E6-AP carboxy terminus) domain-containing E3s. The main 
difference among them is that while RING ligases directly transfer ubiquitin from E2 to 
the target protein, HECT ligases bind ubiquitin to one of their Cys aminoacid right 
before transferring it to the target protein (de Bie & Ciechanover). Once the ubiquitin is 
bound to the protein of interest, the latter can either be driven to degradation through 
the 26S proteasome (the ubiquitin proteins will be recycled), or de-ubiquitinated by 
DUBs (de-ubiquitylating enzymes) enzymes, which only a few types are known at 
present. 
Some studies seem to suggest that labeling proteins by means of ubiquitination 
is not only a direction for degradation but also a target to enroll the cell in many other 
processes such as cell cycle, DNA repair, endocytosis, antigen processing and 
apoptosis (Di Fiore et al, 2003; Haglund & Dikic, 2005). In addition to that, it has been 
shown that besides ubiquitin there are other kinds of similar modifications known as 
ubiquitin-like proteins (Ubl) (figure 6) which include: sumoylation (small ubiquitin-related 
modifier; SUMO) (S), fatylation (FAT10) (F), neddylation (NEDD8) (N) and ISGylation 
(interferon-stimulated gene 15; ISG15) (figure 6, i), in a functionally distinct manner 
(Hoeller et al, 2006). 
 
Figure 6. Summary of the most important ubiquitin-like proteins (Ubl). The arrows point to the 
outcomes each Ubl has in the cell. 
It is not surprising to think that this important cell signalling regulation must be 
ruled very tightly. SIAH2 expression is controlled either at the mRNA level or at the 
protein level by restriction via self-ubiquitination, while its activity can be regulated 
through the association with different binding proteins (Depaux et al, 2006; Matsuzawa 
& Reed, 2001; Nakayama et al, 2004). Nevertheless, it is surprising how little is known 
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as regards how post-translational modifications are able to alter SIAH2 activity. Murine 
Siah2 is phosphorylated by p38 MAPK, which in turn increases its ability to degrade 
PHD3 (Khurana et al, 2006), while previous work from us showed that phosphorylation 
of human SIAH2 by the serine/threonine kinase HIPK2 (homeodomain-interacting 
protein kinase) occurs at three residues, affecting its activity through the modification of 
substrate interaction (Calzado et al, 2009a). This work also revealed the strong 
phosphorylation of SIAH2 at many residues, raising the possibility that several kinases 
mediate SIAH2 phosphorylation. The phosphorylation of SIAH2 weakens its interaction 
with HIPK2, a kinase that belongs to the CMGC (containing CDK, MAPK, GSK, CLK 
families) group of protein kinases. The CMGC group, also comprises the dual-specifity 
tyrosine phosphorylation regulated (DYRK) kinases which includes DYRK1a, DYRK1b 
and DYRK2 (Becker et al, 1998).  
 
8. SIAH2 and Hypoxia 
Oxygen tension in the body is crucial for the maintenance of body balance upon 
different physiological conditions. For instance, O2 regulation is critical on stroke, 
cancer, hypertension, sleep apnoea, heart failure and sudden infant death syndrome. 
The reason why hypoxia occurs is mainly due to three different motives: lack of O2 
transport, low partial pressure and inability of tissues to accept O2. According to the 
oxygen level in the tissue in question hypoxia can be divided into four major types: a) 
Hypoxic hypoxia, due to pulmonary diseases or low oxygen abundance in the 
atmosphere, typically present at high altitudes; b) Anaemic hypoxia, due to a lack of 
haemoglobin which is normally caused by a loss of blood, reduced red cell production, 
genetic defect of haemoglobin or carbon monoxide poisoning; c) Ischemic or Stagnant 
hypoxia, which results as low flow of blood due to vasospasms, atherosclerosis or 
heart failure and d) Histotoxic hypoxia, which prevents the tissue to accept coming 
oxygen due to poisoning of oxidative enzymes. In order to face these abnormal 
situations, the organism undergoes a wide number of changes. At a cellular level for 
instance, the oxygen-sensitive ion channels (K+ and Ca2+ channels) are inhibited 
(Peers, 1997) and, on the other hand, HIF-1 action comes into play. 
As it is reported in the literature, SIAH2 has been described as a key protein in 
cancer, hypoxia and inflammation processes (House et al, 2006; House et al, 2009; 
Kim et al; Nakayama et al, 2004; Qi et al). As regards the role of SIAH2 in hypoxia, it is 
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worth pointing out its ability to alter the expression of hypoxia-inducible transcription 
factor 1 alpha (HIF-1α) (Nakayama et al, 2009) (Appelhoff et al, 2004) (Nakayama et 
al, 2004) by down-regulating PHDs 1 and 3 enzymes. Furthermore, it has been 
reported very recently that under hypoxia events the intracellular domain of p75 
Neurotrophin Receptor increases SIAH2 stabilization by decreasing its auto-
ubiquitination, and therefore a rise in HIF-1α levels occurs (Le Moan et al). In contrast, 
under normal conditions of O2, SIAH2 basal levels are not enough to degrade PHDs 
which in turn hydroxylate HIF-1α sparking off its proteasomal degradation (Ivan et al, 
2001; Jaakkola et al, 2001). 
HIF-1, whose levels vary the opposite way as O2 concentration does (Ferguson 
et al, 2007), is a transcripion factor that rule a wide number of genes involved in 
important cellular processes (Kaelin, 2005; Schofield & Ratcliffe, 2004; Semenza, 
2003). It is a heterodimer made up of two Basic Helix-Loop-Helix (bHLH) proteins that 
belong to the PAS family of proteins. While HIF-1β or aryl hydrocarbon nuclear 
translocator (91-94 kDa) subunit is constitutively expressed, the other component, HIF-
1α (120 kDa), is induced upon a lack of oxygen and very fast degraded by the 
proteasome. Besides HIF-1α, HIF-2α and HIF-3α proteins have been described (Hirota 
& Semenza, 2005). As it is seen in figure 7, PHD hydroxylates HIF-1α at Pro-402 and 
Pro-564 in normoxia and mild hypoxia conditions. Once this occurs pVHL (the von 
Hippel-Landau tumour supressor gene product) recognizes hydroxylated HIF-1α and 
forms a complex with elongin B, elongin C, RBX1 and Cullin 2 for_further HIF-1α 
ubiquitination and subsequent degradation by means of the proteasome. Acetylation of 
HIF-1α at lysine-532 by the ARD1 acetyltransferase enhances the interaction of VHL 
with HIF-1α. Under hypoxa events, SIAH2 limits PHD1 and PHD3 availability, thereby 
increasing HIF-1α expression! (Hon et al, 2002; Iwai et al, 1999; Jeong et al, 2002; 
Kibel et al, 1995; Nakayama et al, 2004; Pause et al, 1997). 
HIF-1 regulation in the cell is not only achieved at a protein level, but also at a 
transcriptional level by means of FIH (factor inhibiting HIF-1α) (Mahon et al, 2001), 
which is another hydroxylase factor that belongs to the Fe2+- and 2-oxoglutarate-
dependent dioxygenase superfamily (Hirota & Semenza, 2005; Mahon et al, 2001). It 
hydroxylates HIF-1α at Asparagine-803 residue, thereby preventing its phosphrylation 
prior to dimerize with HIF-1β. This modification makes it unavailable to associate with 
p300/CREB for transcriptional activation of some genes (i.e. HIF-1α for self regulation). 
The levels of FIH in mammalian cells are not O2-dependent (Stolze et al, 2004) and its 
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regulation still remains to be elucidated. However, it has been reported in the literature 
that SIAH1 mediates FIH degradation under normoxic conditions (Fukuba et al, 2008). 
Also, it has been shown that ISWI is required for full expression of FIH mRNA and 
protein levels by changing RNA polymerase II loading to the FIH promoter (Melvin et 
al). In short, under hypoxic conditions prolyl- and asparaginyl-hydroxylases are 
inhibited, thereby preventing hydroxylation of HIF-1α which will dimerize with HIF-1β to 
activate HRE (hypoxia-response elements) in HIF target genes. 
 
 
Figure 7. A straighforward model on how HIF regulation occurs. 
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 Endocannabinoids may play a major role in the central nervous system (CNS), 
immune control and neuroprotection by regulating the cellular network of 
communication between the nervous and immune system during neuroinflammation 
and neuronal damage. In this sense, we define how NADA is able to regulate the 
activity of p38 and SIAH2 proteins, being the latter an important regulator of the 
hypoxic and cancer responses. This tesis drove us to the discovery of new kinases 
able to phosphorylate and regulate SIAH2 activity and to understand a new molecular 
mechanism by which hypoxic cancer cells could escape chemotherapeutic drug 
treatment. 
 
The aims of this search project have been the followings: 
1. Studying the effects of NADA on target proteins that mediate 
inflammation and tumorigenesis. 
 
2. Identifying new kinases able to phosphorylate SIAH2. 
 
3. Resolving one possible molecular mechanism whereby SIAH2 regulation 
alters angiogenesis. 
! 
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1. Cell lines, transfections and reagents 
 U2OS (human osteosarcoma cell line), b.end5 (murine brain endothelial cell 
line), HeLa (cervical cancer cells), H1299 (human non-small cell lung carcinoma cell) 
and HEK 293T (human embryonic kidney cells) cells were maintained in DMEM 
supplemented with 10% FCS, 2 mM L-glutamine and 1% (v/v) penicillin/streptomycin at 
37 ºC in a humidified atmosphere containing 5% CO2. HUVEC (Human Umbilical Vein 
Endothelial Cells) cells were maintained in Medium 199 supplemented with 20% FBS, 
2 mM penicillin/streptomycin (10000 U y 10 mg/ml, respectively), 2 mM amphotericin B, 
2 mM L-glutamine, 10 mM Hepes, 30 μg/ml ECGS and 100 μg/ml heparine. Transient 
transfections were performed with Rotifect (Roth) according to manufacturer 
instructions and harvested 48h after transfection. HUVEC cells were transfected using 
the nucleofector technology (Lonza). DNA amounts in each transfection were kept 
constant upon addition of empty expression vector. 
 Hypoxia was induced by cultivation of cells in a New Brunswick Innova-48 
incubator at defined O2 concentrations. MG-132 was purchased from Enzo biolabs. 
Doxorubicin, N-arachidonoyl-dopamine (NADA), cycloheximide (CHX), SB203580, 
Harmine and the rest of reactives were from Sigma Aldrich. Scramble control 
oligonucleotides siRNA (#D-001810-10-20) and the siGENOME SMARTpool (#M-
006561-02) against SIAH-2 were purchased from Dharmacon (#M-006561-02). 
Oligonucleotides Stealth siRNA against DYRK2 (5’-
AUACCUGUAAGCCACGUGAUCGUGG-3’) were from Invitrogen. The effect of siRNA 
on protein expression was assessed 2 days after transfection. 
 
2. Antibodies 
 Antibodies against FLAG epitope (clone M2), β-actin (AC-74) and α-tubulin 
were purchased from Sigma Aldrich. Anti-phospho-JNK 1+2 (9255S), anti-phospho p38 
(Thr180/Tyr182, 9211), anti-p53 (sc-126), anti-p53 phospho Ser46 (2521) and anti-
ubiquitin (P4D1) from Cell Signaling Technology. Antibodies against COX-2 (M-19), 
COX-1 (M-20), phospho-ERK 1+2 (sc-7383) and SIAH2 (sc-5507) were from Santa 
Cruz. Anti-DYRK2 (AP7534a) from Abgent, anti-HA (clone 3F10) and anti-myc (clone 
9E10) from Roche Molecular Biochemicals, anti-phosphoserine (AB1603) from 
Millipore. Rabbit polyclonal antibodies recognizing phosphorylated threonine 26 and 
serines 28 and 68 of SIAH2 were raised by NeoMPS. Rabbit polyclonal antibodies 
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recognizing phosphorylated threonine 119 of SIAH2 were raised by Abyntek. 
Secondary horseradish peroxidase-coupled antibodies were purchased from Jackson 
ImmunoResearch Laboratories. The Alexa Fluor 647 goat anti-mouse IgG1 and Alexa 
Fluor 488 goat anti-rabbit IgG antybodies were purchased from Invitrogen. 
 
3. Plasmids 
 Flag-SIAH-2 wild type sequence, Flag-SIAH-2-RM (Ring Mutant, H98A/C101A), 
HA-Ubiquitin and His-Ubiquitin were described previously (Calzado et al, 2009). Flag-
DYRK1A and Flag-DYRK1B were reported formerly (Ritterhoff et al). Flag-DYRK2 and 
Flag-DYRK2-KD (Kinase Death, K251R) plasmids were detailed earlier (Gwack et al, 
2006). HA-SIAH2 and HA-SIAH2-RM were generated by PCR following standard 
protocols. Myc-DYRK2 was cloned into pCMV-Tag3B-Myc by amplification by PCR 
using the following primers: Forward: 5’ GGGGGAATTCATGAATGATCACCTGCATGT 
3’ y Reverse: 5’ GGGGAAGCTTTCAGCTAACAAGTTTTGGCA 3’. The PCR program 
consisted of a first denaturing cycle (2 min at 94ºC), followed by 35 cycles of three 
steps: denaturing (30 sec at 94ºC), annealing (30 sec at 65ºC) and elongation (1 min 
and 15 sec at 68ºC), finally the DNA was further elongated in the last cycle (10 min at 
72ºC). As a result we obtained two new restriction enzyme cuts (EcoRI y HindIII) that 
were checked on an agarose gel. Finally, the sequence was confirmed by sequencing. 
The p53-Luc (containing multimers of p53-binding sites) and Bax-Luc reporter plasmids 
were previously described (Fogal et al, 2000; Hofmann et al, 2002). The plasmid COX-
2-Luc was a gift from Dr. M. Iñiguez (UAM, Spain); this plasmid contains the COX-2 
promoter followed by the luciferase gene. The COX-2 translational reporter COX-2–3'-
UTR-luciferase contains the 3´-UTR of COX-2 sequence (763 bp) fused to the 3´ end of 
the luciferase gene under control of the SV40 promoter and enhancer elements (Yeo et 
al, 2003). pcDNA3-Flag-PHD3 was a gift from Dr. Frank S. Lee (Pennsylvania School of 
Medicine), pGEX-2TK-DYRK2 was a gift from Dr W Becker (Aachen, Germany) and 
Epo-Luc was a gift from Dr. ML. Schmitz (Giessen, Germany). Human SIAH-2-WT, 
SIAH-2-ΔC (aminoacids 117-324) and SIAH-2-ΔN (aminoacids 1-116) were cloned in 
pGEX-2TK allowing prokaryotic expression of SIAH-2 as a GST fusion protein. The 
primers used were: SIAH-2-WT-Fwd: 5’ 
GCAGGAATTCATGAGCCGCCCGTCCTCCACCGGC 3’, SIAH-2-WT-Rev: 5’ 
CCCCCTCGAGTCATGGACAACATGTAGAAATAGTAAC 3’, SIAH-2-ΔC-Fwd: 5’ 
GCAGGAATTCATGAGCCGCCCGTCCTCCACCGGC 3’, SIAH-2-ΔC-Rev: 5’ 
Materials and methods!
!
21!
GGGCCTCGAGTCAGCCCCTGCACGTCGGGCAG 3’, SIAH-2-ΔN-Fwd: 5’ 
GATTGAATTCGCCCTGACGCCCAGCATCAG 3’, SIAH-2-ΔN-Rev: 5’ 
CCCCCTCGAGTCATGGACAACATGTAGAAATAGTAAC 3’. The PCR program 
consisted of a first denaturing cycle (2 min at 95ºC), followed by 40 cycles of three 
steps: denaturing (1 min at 95ºC), annealing (1 min at 95ºC) and elongation (1 min at 
72ºC), finally the DNA was further elongated in the last cycle (5 min at 72ºC). The 
following SIAH-2 point mutants were previously described: T26A, S28A, S68A, 
TS2628AA, SS2868AA y TSS262868AAA, T113A, T119A, S121A y S279A (Ritterhoff 
et al). The following SIAH-2 point mutants: S16A, S16D, TS2628DD, S68D and T119D 
used to create the final SIAH-2-STSST16262868119AAAAA (SIAH-2-5A) y SIAH-2-
STSST16262868119DDDDD (SIAH-2-5D) mutants, were prepared using the 
QuickChange site-directed Mutagenesis Kit (Stratagene, # 210518). The authenticity of 
the constructs was verified by DNA sequencing. The PCR program consisted of a first 
denaturing cycle (2 min at 95ºC), followed by 18 cycles of three steps: denaturing (1 
min at 95ºC), annealing (1 min at 60ºC) and elongation (8 min at 68ºC), finally the DNA 
was further elongated in the last cycle (10 min at 68ºC).  
 
4. Western blotting  
 Soluble fractions were obtained after lysis of cells in NP-40 buffer (20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1 mM phenylmethylsulfonylfluoride, 10 mM NaF, 0.5 mM 
sodium orthovanadate, leupeptine (10 μg/ml), aprotinin (10 μg/ml), 1% (v/v) NP-40, and 
10% (v/v) glycerol). After centrifugation the supernatants were mixed with SDS sample 
buffer (50mM Tris-HCl pH6.8, 100mM DTT, 2% SDS, 0.1% bromophenol blue and 10% 
glycerol). Proteins were resolved on SDS-PAGE gels and blotted to polyvinylidene 
difluoride membranes using a semi-dry transfer. After blocking with non fat milk or BSA 
in TBST buffer, primary antibodies were added. Appropriate secondary antibodies 
coupled to horseradish peroxidase were detected by enhanced chemiluminescence 
system (USB). 
 
5. Phosphatase treatment 
 Cells were lysed in NP-40 buffer without phosphatase inhibitors. Then samples 
were treated with γ-phosphatase following manufacturer’s instructions (New England 
Biolabs). Reactions were stopped with SDS buffer and samples inmunoblottted. 
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6. Immunoprecipitation  
 Cells were washed in PBS and collected by centrifugation. The cell pellet was 
lysed in IP buffer [50 mM Hepes pH 7.5, 50 mM NaCl, 1% (v/v) Triton X-100, 2 mM 
EDTA, 10 mM sodium fluoride, 0.5 mM sodium orthovanadate, 10 μg/ml leupeptine, 10 
μg/ml aprotinin, 10 μg/ml aprotinin, 10 μg/ml leupeptin and 1 mM PMSF]. Cell lysates 
were incubated with 1 μg of the indicated antibodies for 6 h at 4 ºC. Antibodies were 
then isolated with 25 μl of protein A/G Sepharose (Santa Cruz). Imnunoprecipitated 
proteins were then washed five times in IP buffer and eluted in 1.5X SDS sample 
buffer. Samples were immunoblotted as described before. 
 
7. Luciferase reporter assays 
 Cells were collected in PBS and lysed in NP-40 buffer or Triton buffer (25 mM 
Tris-phosphate pH 7.8, 8 mM MgCl2, 1 mM DTT, 1% Triton X-100, and 7% glycerol). 
Luciferase assay was performed using Luciferase Assay Reagent (Promega) according 
to the manufacturer’s instructions and measured in a luminometer Autolumat LB9510 
(Berthold). Luciferase activity in different samples was normalized with protein 
concentration. 
 
8. Enrichment of His-Tagged Proteins 
 Cells were collected in PBS and pellets were dissolved in lysis buffer (50 mM 
Tris-HCl buffer pH 8.0 containing 8M urea, 50 mM Na2HPO4, 300mM NaCl, 0.5 % (v/v) 
NP-40, 10 mM imidazole and 1 mM β-mercaptoethanol). Samples were sonified and 
cell debris were removed by centrifugation. His-ubiquitin tagged proteins were isolated 
with 40 μl of equilibrated Ni-NTA resin (Qiagen) for 4h at room temperature. After 
centrifugation precipitates were washed once with lysis buffer, once with wash buffer 1 
(10 mM Tris HCl, pH 8.0 containing 8M Urea, Na2HPO4 100 mM,10 mM imidazole and 
1 mM β-Mercaptoethanol) and twice with Wash buffer 2 (the same composition of wash 
buffer 1 but at pH 6.3). Proteins were eluted in SDS sample buffer containing 200 mM 
imidazole and analyzed by immunoblotting. 
 
9. Immunofluorescence 
 Cells were grown on coverslips and 48h after transfection fixed with 3,7% of 
pre-warmed paraphormaldehyde/PBS for 10 minutes. Cells were then permeabilized 
with 0,1% Triton X-100/PBS for 15 min, blocked with 3% BSA/PBS and incubated 
overnight with primary antibodies. After being washed with PBS and incubated for 45 
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min with the secondary antibody they were mounted on glass slides with mounting 
medium with DAPI (Vectashield). Fluorescence images were captured using confocal 
laser scanning microscope LSM 5 EXCITER (Carl Zeiss MicroImaging GmbH) using a 
40X/1.30 oil objective (EC Plan-Neofluar) and ZEN 2008 software (Carl Zeiss 
MicroImaging GmbH). Images were analysed using the ImageJ v 1.45 software 
(http://rsbweb.nih.gov/ij/). The Costes’ approach was employed for co-localization 
analysis between green (Alexa 488) and red (Alexa 647) images to determinate the 
Pearson’s correlation coefficient (R). SIAH2 wild type and phospho mutant versions 
were visualized on a BD Pathway 855 Bioimager in a non-confocal mode. 
 
10. GST pulldown assay  
 Recombinant GST-SIAH2 proteins (Wt, ΔC and ΔN) were produced in 
Escherichia coli BL21 cells and purified with Glutathione-Sepharose 4B (GE 
Healthcare) according to standard protocols. HEK 293T cells expressing Flag-DYRK2 
were lysed in IP buffer. Then 400 μg of protein from each lysate were incubated at 4 ºC 
overnight with soluble fusion proteins (10 μg) and 30 μl of glutathione-sepharose 
beads. Sepharose beads were then washed with IP buffer and resuspended in SDS 
sample buffer for further inmunoblot analysis 
 
11. In vitro phosphorylation analysis 
 GST-SIAH2 fusion protein (8 μg) was incubated with 0.5 μg of commercial 
recombinant DYRK2 protein (Abnova) in kinase buffer assay (20 mM Hepes, pH 7.5, 
10 mM MgCl2, 1 mM DTT and 0.1 mM ATP). After 60 min of incubation at 30 ºC 
reactions were stopped adding SDS sample buffer. Samples were then immunoblotted 
with anti-phosphoserine antibody. 
 
12. Mass spectrometry 
 SIAH2 protein was immunoprecipitated with anti-Flag M2 affinity gel (Sigma 
Aldrich) from HEK-293T cells transfected with SIAH2-Flag plasmid alone or combined 
with DYRK2-Myc. Cells were treated with 10 μM 12 h before lysis. After collection 
pellets were lysed in IP buffer. The precipitated proteins were eluted by boiling in 1.5X 
SDS sample buffer for 5 min and resolved in SDS-PAGE gels. SIAH2 bands were 
excised from gels and destained in acetonitrile:water (ACN:H2O, 1:1). Gel bands were 
digested with trypsin (Promega, Madison, WI) as previously described (Shevchenko et 
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al, 1996). Disulfide bonds from cysteinyl residues were reduced with 10 mM 
dithiothreitol (DTT) for 1 h at 57 ºC, and then thiol groups were alkylated with 55 mM 
iodoacetamide for 1 h at room temperature in darkness, and washed once in ACN:H2O 
(1:1) in order to remove excess iodoacetamide. The gel pieces were shrunk by 
removing all liquid using sufficient ACN. Acetonitrile was pipetted out prior to 
desiccation via speedvac. The dried gel pieces were re-swollen in 50 mM ammonium 
bicarbonate with trypsin (12.5 ng/μl). The tubes were kept in ice for 2 h. The digestion 
buffer was removed and gels were covered again with 50 mM ammonium bicarbonate 
and incubated at 37°C for 12 h. Digestion was stopped by the addition of 1% TFA, 
trifluoroacetic acid. Whole supernatants were dried down and then desalted until the 
mass spectrometric analysis. After digestion, TFA was added to a final concentration of 
0.1% and samples were desalted on ZipTip C18 tips (Millipore) using as elution 
solution 50% ACN in 0.1% TFA. 
 The desalted protein digest was dried, resuspended in 7 μl of 0.1% formic acid 
and analyzed by RP-LC-MS/MS in an Agilent 1100 system coupled to a linear ion trap 
LTQ-Velos mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). The 
peptides were separated by reverse phase chromatography using a 0.18 mm × 150 
mm Bio-Basic C18 RP column (Thermo Fisher Scientific), operating at 1.8 μl/min. 
Peptides were eluted using a 35-min gradient from 5 to 40% solvent (Solvent A: 0,1% 
formic acid in water, solvent B 0,1% formic acid, 80% acetonitrile in water). ESI 
ionization was done using a microspray “metal needle kit” (Thermo Fisher Scientific) 
interface. Peptides were detected in survey scans from 400 to 1600 amu (1 μscan), 
followed by five data dependent MS/MS scans (Top 5), using an isolation width of 2 u 
(in mass-to-charge ratio units), normalized collision energy of 35%, and dynamic 
exclusion applied during 30 seconds periods. Peptide identification from raw data was 
carried out using the SEQUEST algorithm (Proteome Discoverer 1.2, Thermo Fisher 
Scientific). Database search was performed against a small home database containing 
Siah-2 sequence. The following constraints were used for the searches: tryptic 
cleavage after Arg and Lys, up to two missed cleavage sites, and tolerances of 1 Da for 
precursor ions and 0.8 Da for MS/MS fragment ions and the searches were performed 
allowing optional Met oxidation and Cys carbamidomethylation. To identify 
phosporylated peptides, phosphorylation on Ser or Thr was added as a variable 
modification. 
 In order to confirm the phosphorylations identified by the above method and to 
identify new sites, the mass spectrometer was operated in the selected MS/MS ion 
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monitoring mode. In this mode, the LTQ-Velos detector was programmed to perform, 
along the entire gradient, a continuous sequential operation in the MS/MS mode on the 
doubly charged and triple charged ions corresponding to the peptide/s selected 
previously. The MS/MS spectra from the peptide were analyzed by assigning the 
fragments to the candidate sequence, after calculation the series of theoretical 
fragmentations, according to the nomenclature of the series as previously described 
(Roepstorff & Fohlman, 1984). The proportion of each phosphorylated peptide was 
estimated using the fragments of MS / MS spectra which are common to the modified 
and unmodified peptides. In order to normalize we used a non-phosphorylated control 
peptide present in all samples. 
 
13. Peptide array binding assay 
 Overlapping dodecapeptides of SIAH2 protein were automated spotted on 
cellulose membranes by using Fmoc-protection chemistry. Membrane was blocked 
overnight in non fat milk in TBS buffer and incubated during 6 hours with 60 nmol of 
recombinant GST-DYRK2 protein or GST protein for control. Then primary anti-DYRK 
antibody was added and rabbit secondary antibodies coupled to horseradish 
peroxidase were revealed by enhanced chemiluminescence system (USB) on 
autoradiographic films. 
 
14. mRNA extraction and qPCR 
 Cells were harvested and washed twice with PBS. The cell pellet was lysed 
using the RNeasy Mini Kit (Qiagen) so as to isolate the RNA. After being quantified in a 
spectrophotometer (Genessis 10 uv Scanning, Thermo Scientific), RNA integrity was 
checked on an agarose gel (Bio-Rad Universal Hood II). mRNA retrotranscription was 
performed with the iScript cDNA Synthesis  kit (Bio-Rad). Real time PCR was 
employed with go taq qPCR Master Mix (Promega) in an iCYCLER detection system 
(Bio-Rad). The qPCR program for COX-2 amplification consisted of a first denaturing 
cycle (3 min at 95 ºC), followed by 40 cycles of four steps: denaturing (30 sec at 95 ºC), 
annealing (30 sec at 50 ºC), elongation (30 sec at 72 ºC) and a further step (10 sec at 
83 ºC) . The DNA was finally elongated in the last cycle (1 min at 72 ºC). The qPCR 
program for DYRK2 amplification consisted of a first denaturing cycle (2 min at 95 ºC), 
followed by 35 cycles of three steps: denaturing (15 sec at 95 ºC), annealing (59 sec at 
59 ºC) and elongation (30 sec at 72 ºC), finally the DNA was further elongated in the 
last cycle (10 min at 72 ºC). The following primers were used: COX-2-Forward: 5´ 
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TGAGCAACTATTCCAAACCAGC 3´; COX-2-Reverse: 5´ 
GCACGTAGTCTTCGATCACTATC 3´ GAPDH-Forward: 5´ 
TGGCAAAGTGGAGATTGTTGCC 3´ and GAPDH-Reverse, 5´ AAGATGGTGA 
TGGGCTTCCCG 3´, DYRK2-Forward: 5’ GTGGTCAAGGCCTACGATCACA 3’, 
DYRK2-Reverse: 5’ CCGCAGGTGTTCCAGGATTC 3’, β-Actin-Forward: 5’ 
GCTCCTCCTGAGCGCAAG 3’ and β-Actin-Reverse: 5’ 
CATCTGCTGGAAGGTGGACA 3’. Amplification efficiencies of COX-2 and DYRK2 
were validated and normalized against GAPDH and β-Actin, respectively. The fold 
change in gene expression was calculated using delta CT method. 
 
15. Angiogenesis assay 
 5x105 HUVEC cells were transfected by electroporation using the nucleofector 
technology (Lonza). Twenty-four hours after transfection, cells were harvested and 2 
x104 cells were reseeded over a uniform layer of matrigel (BD Biosciences) in 96 well 
plate. After twelve hours cells were washed with PBS and stained with 5 μM Calcein 
(Invitrogen). Tubes formations were analyzed using a 4X objective and the BD Pathway 
855 Bioimager. For quantification of tubes total length and tubes branch points 
Attovission v 1.7 BD software was used. The remainder of cells was reseeded on 6 
well plates and twelve hours later were collected for expression analysis of SIAH2 
levels by inmunoblotting. 
 
16. Determination of COX-2 protein degradation half-life 
 b.end5 cells were preincubated with vehicle or NADA (2.5 µM) during 12 hours 
and then cycloheximide (CHX, 10 µM) was added to inhibit further protein synthesis. 
Following incubation for 1, 2, 4 and 6 h, cells were harvested and lysed, and cell 
lysates were collected as described above. Western blotting was performed in the 
same way as described above. Normalized density ratio of COX-2 over α-tubulin was 
performed using the Quantity One program (Bio-Rad). Protein degradation rate is 
expressed as half-life (t1/2), the time for degradation of 50% of the protein. 
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1. N-Arachidonoyl-dopamine induces the expression of COX-2 on brain 
endothelial cells 
 To study the effects of NADA on COX-1 and COX-2 protein expression we 
treated b.end5 cells with increasing concentration of NADA during 20 h and the steady 
state levels of COX-1, COX-2 and α-tubulin were investigated by western blots. COX-
2/COX-1 optical density values were normalized to α-tubulin and represented in 
arbitrary units. In Figure 8, it is shown that NADA, at the concentration of 1 mM and 
higher, clearly increased the expression of COX-2, but not COX-1, in b.end5 cells. 
 
 
Figure 8. NADA induces COX-2 protein expression in b.end5 cell line in a dose-
dependent manner. b.end5 cells were incubated with NADA at the indicated doses during 20 
hours. The expression of COX-1 and COX-2 protein was determined by immunoblot analysis of 
protein levels. We reported the representative blots and mean ± S.D. values of optical density of 
three independent experiments (one-way ANOVA with Student’s t-test ** P < 0.001 and for 
NADA versus control). 
  
2. N-Arachidonoyl-dopamine stabilizes COX-2 mRNA in brain endothelial cells 
 It has been reported that COX-2 undergoes proteasomal degradation via the 
endoplasmic reticulum-associated degradation pathway! (Mbonye et al, 2006). To 
investigate the mechanisms by which NADA induces the expression of COX-2 in 
b.end5 cells firstly we studied the half-life of the COX-2 protein. The cells were treated 
with vehicle or with NADA (2.5 mM) during 12 h, then CHX (10 mM) was added and the 
cells were collected at the indicated times. Finally, the expression of COX-2 and α-
tubulin protein was analyzed by immunoblots. As expected, NADA induced a clear 
increase in COX-2 expression (Figure 9A). The specific bands were quantified and the 
ratio COX-2/α-tubulin calculated for every point and plotted to calculate the decay rates 
2.5. Determination of COX-2 protein degradation half-life
b.end5 cells were preincubated with vehicle or NADA (2.5mM)
during 12 h and then cycloheximide (CHX, 10 mM) was added to
inhibit further protein synthesis. Following incubation for 1, 2, 4
and 6 h, cells were harvested and lysed, and cell lysates were
collected as described above. Western blotting was performed in
the sameway as described above. Normalized density ratio of COX-
2 over a-tubulin was performed using the Quantity One program
(Bio-Rad). Protein degradation rate is expressed as half-life (t1/2),
the time for degradation of 50% of the protein.
2.6. Determination of COX-2 mRNA half-life
b.end5 cells were preincubated with vehicle or NADA (2.5mM)
during 12 h and then Actinomycin D (Act-D, 10 mM) was added to
inhibit general gene transcription. Following incubation for 1, 2, 4
and 6 h, cells were harvested and total RNA was isolated by using
the kit RNAspin Min (GE Healthcare). Total RNA was used to study
the expression of COX-2 gene by qRT-PCR analysis as described
subsequently and mRNA half-life (t1/2) was calculated by linear
regression analysis.
2.7. qRT-PCR
b.end5 cells were stimulated as indicated and total RNA was
isolated by using the kit RNAspinMin (GE Healthcare) according to
the manufacturer’s instructions. Onemg of total RNA served as the
template for single strand cDNA synthesis in a reaction using Oligo
(dT) primers and SuperScriptTM II RNase H- Reverse Transcriptase
(Invitrogen Ltd., San Diego, USA) according to the manufacturer’s
protocol. For quantitative RT-PCR analysis expression we used the
iCycler (Bio-Rad) system. Equal amounts of cDNA were used in
triplicate and amplified with the specific primers. The PCRmixture
consisted of 50 ml containing 1 ml of cDNA, 25ml of 2! SYBRGreen
Supermix (100 mM KCl, 40 mM Tris–HCl pH 8.4, 0.4 mM of dNTP,
50 u/ml iTaq polimerasa, 6 mM MgCl2, SYBR Green I, 20 nM
fluorescein and stabilizers), and 0.2 mM concentration of each
sequence-specific primer. The primers used were as follows:
COX-2 sense primer, 50TGAGCAACTATTCCAAACCAGC30;
COX-2 antisense primer, 50GCACGTAGTCTTCGATCACTATC30;
L-PGDS sense primer, 50GCTCTTCGCATGCTGTGGAT30;
L-PGDS antisense primer, 50GCCCCAGGAACTTGTCTTGTT30;
mPGES-1 sense primer, 50AGCACACTGCTGGTCATCAA30;
mPGES-1 antisense primer, 50CTCCACATCTGGGTCCACTCC30;
GAPDH sense primer, 50TGGCAAAGTGGAGATTGTTGCC30;
GAPDH antisense primer, 50AAGATGGTGATGGGCTTCCCG30.
The amplification profile consisted of an initial denaturation for
3 min at 95 8C and then 40 cycles of 30 s at 95 8C, annealing for 30 s
at 50 8C, and elongation for 30 s at 72 8C. A cycle of 10 s at 83 8C and
a final extension for 1 min was carried out at 72 8C. Amplification
efficiencies were validated and normalized against GAPDH, and
fold increases were calculated by using the comparative threshold
cycle method for quantification.
2.8. Determination of PGE2 and PGD2 by enzyme immunoassay
Supernatants were harvested, centrifuged at 10,000 ! g for
10 min and levels of PGE2 or PGD2 in the media were measured
by enzyme immunoassay (EIA) (Cayman Chemicals, Ann Arbor,
MI, USA) according to the manufacturer’s instructions. For the
PGE2 assay the standards were used in the interval of 7.8 to
1.000 pg/ml (detection limit of 15 pg/ml). For the PGD2 assay the
standards were used in the interval of 78 to 10,000 pg/ml
(detection limit approximately 200 pg/ml). To calculate con-
centrations of PGs outside the limit of detection, dilutions of the
supernatants were used.
2.9. Statistical analysis
At least three independent experiments were used for data
analysis. Statistical analysis was performed using one-way ANOVA
analysis. In the case of a significant result in the ANOVA, Student’s
t-test was used for dose–response assays and Bonferroni’s test was
used for post-hoc analysis for all other experiments. Data are
reported as mean values " standard error of mean (S.E.M.).
3. Results
3.1. N-Arachidonoyl-dopamine induces the expression of COX-2 on
brain endothelial cells
The murine brain endothelial cell line b.end5 is a recognized
model to study blood–brain barrier cell function [41]. To study the
effects of NADA on COX-1 and COX-2 protein expression e
treated b.end5 cells with increasing concentration of NADA during
20 h and the ste dy state levels of COX-1, COX-2 and a-tubulin
were investigated by western blots. COX-2/COX-1 optical density
values were normalized to a-tubulin and represented in arbitrary
units. In Fig. 1A, it is shown that NADA, at the concentration of
1mM and higher, clearly increased the expression of COX-2, but
not COX-1, in b.end5 cells. NADA is a mixed agonist of CB1 and
Fig. 1. NADA induces COX-2 protein expression in b.end5 cell line in a dose-
dependent manner. (A) b.end5 cells were incubated with NADA at the indicated
doses during 20 h. The expression of COX-1 and COX-2 protein was determined by
immunoblot analysis of protein levels. We reported the representative blots and
mean " S.D. values of optical density of three independent experiments (one-way
ANOVA with Student’s t-test **P < 0.001 and for NADA versus control). (B) b.end5 cells
were pretreatedwith CB1 antagonist, SR141716A (1 mM) and TRPV1 antagonist, 50IRTX
(0.1 mM) during 30 min before NADA (2.5 mM). Protein extracts were prepared after
20 h incubation with the compounds, and subjected to SDS-PAGE. We show a
representative blot out of three independent experiments.
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for COX-2 protein expression (Figure 9B). We found that the half-life (t1/2) for COX-2 
protein in b.end5 cells was approximately 6 h and this half-life was not modified by the 
treatment with NADA. These results, together with the inability of NADA to induce 
COX-2 phosphorylation (data not shown), suggest that protein post-translational 
modifications are not involved in COX-2 stabilization in NADA-treated cells. 
 
 
Figure 9. NADA does not affect the half-life of COX-2 protein. A. b.end5 cells were pre-
incubated with vehicle or NADA (2.5 µM) during 12 hours and then cycloheximide (CHX 10 µM) 
was added to inhibit further protein synthesis. Following incubation from 0 to 6 hours, the cells 
were harvested and the expression of COX-2 protein was determined by immunoblot analysis. 
Normalized density ratio of COX-2 over α-tubulin is indicated for each band. A representative 
blot out of three independent experiments is shown. B. The graph represents the COX-2 protein 
levels normalized to α-tubulin. Results from the densitometry analysis were expressed as 
arbitrary values and plotted relative to the zero time point. 
 
 Next, we studied whether or not NADA had some effect on the COX-2 gene at 
the transcriptional level. The cells were transiently transfected with the COX-2-Luc 
plasmid and 24 h later stimulated with either LPS or NADA during 12 h and the cell 
lysates tested for luciferase activity. We show in Figure 10A that LPS clearly induced 
luciferase expression driven by the COX-2 promoter (4.2-fold induction). In contrast, 
NADA did not affect the basal levels of luciferase when compared to untreated cells. 
However, qRT-PCR experiments demonstrated that NADA induced a clear induction of 
the COX-2 mRNA levels in b.end5 cells (Figure 10B). These results suggest that the 
effects of NADA on COX-2 expression could be mediated by a mechanism that 
involves COX-2 mRNA stabilization. 
Fig. 3. NADA does not affect the half-life of COX-2 protein. (A) b.end5 cells were pre-incubated with vehicle or NADA (2.5mM) during 12 h and then cycloheximide (CHX
10mM) was added to inhibit further protein synthesis. Following incubation from 0 to 6 h, the cells were harvested and the expression of COX-2 protein was determined by
immunoblot analysis. Normalized density ratio of COX-2 over a-tubulin is indicated for each band. A representative blot out of three in ependent experiments is shown. (B)
The graph represents the COX-2 protein levels normalized toa-tubulin. Results from the densitometry analysis were expressed as arbitrary values and plotted relative to the
zero time point.
Fig. 4.NADA stabilizes COX-2mRNA. (A) b.end5 cells were transiently transfected with the luciferase reporter plasmid COX-2-Luc as described inMaterials andMethods and
24 h after transfection the cells were incubated for 12 h with LPS or NADA, and the luciferase activity measured in the cell lysates. Results are the means ! S.D. of three
determinations expressed as fold induction (observed experimental RLU/basal RLU in absence of any stimuli) (one-way ANOVAwith Student’s t-test **P < 0.001 LPS versus control).
(B) For the qRT-PCR analysis of COX-2 expression, b.end5 cells were stimulated with NADA 2.5 mM for 12 h, total RNA extracted and qRT-PCR assay was performed. The graph shows
themeans ! S.D. of three experiments (***P < 0.0001 NADA versus control). (C) b.end5 cells were pre-incubatedwith vehicle or NADA (2.5 mM) during 12 h and then Actinomycin D
(Act-D 10 mM) was added. Following incubation from 0 to 6 h the COX-2 gene expression was determined by qRT-PCR analysis. Amplification efficiencies were validated and
normalized against GAPDH expression. The graph shows the COX-2 gene expression level when incubated with NADA (2.5 mM) and its quantification as compared to the level
obtained with the vehicle. The graph shows the means ! S.D. of three experiments. (D) The graph represents the COX-2 gene expression determined by qRT-PCR analysis expressed
as arbitrary values. mRNA half-life (t1/2) was determined using linear regression analysis. Data at each time point represent the means ! S.D. from three replicates.
C.M. Navarrete et al. / Biochemical Pharmacology 79 (2010) 1805–1814 1809
Results 
 
30 
 
Figure 10. NADA stabilizes COX-2 mRNA. A. b.end5 cells were transiently transfected with 
the luciferase reporter plasmid COX-2-Luc as described in Materials and Methods and 24 h 
after transfection the cells were incubated for 12 h with LPS or NADA, and the luciferase activity 
measured in the cell lysates. Results are the means ± S.D. of three determinations expressed 
as fold induction (observed experimental RLU/basal RLU in absence of any stimuli) (one-way 
ANOVA with Student’s t-test **P < 0.001 LPS versus control). B. For the qRT-PCR analysis of 
COX-2 expression, b.end5 cells were stimulated with NADA 2.5 µM for 12 h, total RNA 
extracted and qRT-PCR assay was performed. The graph shows the means ± S.D. of three 
experiments (***P < 0.0001 NADA versus control). 
 
3. N-Arachidonoyl-dopamine stabilizes COX-2 mRNA through a p38 MAPK 
pathway 
 The COX-2 mRNA is stabilized by p38 MAPK activation in different cell types 
(Lasa et al, 2000; Mifflin et al, 2002; Ridley et al, 1998). To study the role of p38 MAPK 
on NADA-induced COX-2 mRNA stabilization we transiently transfected b.end5 cells 
with the COX-2-30-UTR-luciferase plasmid for 24 h and then the cells were stimulated 
with either LPS or NADA, in the presence or absence of SB203580, a chemical p38 
MAPK inhibitor. After 12 h of treatment the cells were collected and the luciferase 
activity measured in the cell lysates. As depicted in Figure 11A, both LPS and NADA 
clearly induced COX-2 mRNA stabilization that was prevented in the presence of 
SB203580. 
 To further confirm the specific role of p38 on NADA-induced COX-2 protein 
expression we stimulated b.end5 cells with NADA for 12 h in the absence or the 
presence of SB203085. In Figure 11B, it is shown that NADA-induced upregulation of 
COX-2 protein was completely prevented by the p38 MAPK inhibitor SB203085. To 
study directly the effect of NADA on p38 MAPK activation, we incubated b.end5 cells 
with NADA (2.5 mM) for the indicated times, and the phosphorylation/activation status 
of p38, JNK, and ERK was investigated by western blots using specific mAbs that 
recognize the phosphorylated forms of these MAPKs. As depicted in Figure 11C, 
0 
1 
2 
3 
4 
5 
Fo
ld 
In
du
cti
on
 !
LPS ! - + - -
NADA (µM)! 1 2.5!- -
A! B!
**!
0 
2 
4 
6 
8 
10 
NADA (2.5µM)! -! +!
Re
lat
ive
 E
xp
re
ss
ion
 L
ev
el! ***!
Figure'3'
Results 
 
31 
NADA induced a sustained activation of the p38 MAPK and did not affect significantly 
the phosphorylation of the MAPKs JNK and ERK. 
 
 
 
Figure 11. NADA induces COX-2 expression by stabilizing mRNA through a p38 
dependent pathway. A. b.end5 cells were transiently transfected with the plasmid COX-2-
3´UTR-Luc and 24 h later the cells were pre-incubated for 30 min with SB203580 (20 µM) and 
stimulated with LPS or NADA as indicated for 12 h. Luciferase activity was measured and the 
results are the means ± S.D. of three determinations expressed as fold induction (observed 
experimental RLU/basal RLU in absence of any stimuli) (one-way ANOVA with post-hoc 
Bonferroni’s test * P < 0.05 for NADA versus control and **P < 0.001 for LPS / NADA versus 
control; *** P < 0.0001 for LPS+SB203580 versus LPS and for NADA+SB203580 versus 
NADA). B. b.end5 cells were pretreated with SB203580 (20 µM), PD98059 (20 µM) or 
SP600125 (10 µM) for 30 min, and then incubated with NADA 2.5 µM for 20 h. The expression 
of COX-2 protein was determined by immunoblot analysis of protein levels. We reported the 
representative blots of three independent experiments. C. The cells were incubated with NADA 
2.5 µM at the indicated times and MAPKs activation detected by immunoblots using specific 
phospho-antibodies. 
 
4. N-Arachidonoyl-dopamine up-regulates HIF-1α 
 Since both endocannabinoids and HIF-1α share common properties in 
neuroprotection (Giusti & Fiszer de Plazas; Harten et al; Pryce et al, 2003) we 
hypothesized whether NADA could influence HIF-1α at a protein level.  The human 
neuroblastoma cell line SK-N-SH was stimulated with deferoxamine (DFX) and 
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increasing amounts of NADA, and HIF-1α expression was analyzed. As observed, 
larger amounts of HIF-1α were detected. As SIAH2 is one of the upper stream proteins 
in the hypoxia response we wondered whether HIF-1α degradation was a collateral 
effect of NADA-dependent SIAH2 degradation. To assess this, 293T cells were treated 
with MG-132 to avoid SIAH2 auto-degradation and SIAH2 protein was analyzed. We 
observed (Figure 12) a decrease in SIAH2 protein in the presence of NADA, which 
explains the mechanism whereby HIF-1α up-regulation is accomplished. 
 
 
Figure 12. NADA up-regulates HIF-1α protein.  A. SK-N-SH cell were treated with 100 μM of 
DFX and 12 hours later cells were stimulated with 1, 5 and 10 μM NADA for 6 hours before 
lysis. Protein expression was anaylzed by immunoblotting. B. 293T cells were transfected with 
the indicated plasmids and 36 h later cells were treated with 10 μM NADA and 30 min later with 
10 μM MG-132 for 12 h before lysis. Protein expression was evaluated by immunoblot with the 
indicated antibodies. 
 
 
 As the literature reports SIAH2 as a new protein of interest in hypoxia and 
tumorogenesis whose activity depends on the degree of its phosphorylation state, we 
were interested in getting to know the molecular mechanism by which SIAH2 activity is 
ruled. To achieve this, we performed a kinase screening to find out new kinases able to 
phosphorylate SIAH2. Among others, we spotted DYRK2 as a new kinase of interest. 
 
5. DYRK2 phosphorylates SIAH2 in vivo and in vitro 
 As our previous work showed that SIAH2 is heavily phosphorylated (Calzado et 
al, 2009) we aimed to identify further kinases with the ability to modify this important E3 
ligase. A set of different kinases was tested to for their ability to phosphorylate SIAH2 in 
vitro. As DYRK kinases showed robust SIAH2 phosphorylation we initially decided to 
focus on this protein family in more detail. To study the ability of these kinases to 
phosphorylate SIAH2 in vivo, 293T cells were transfected to express SIAH2 and the 
most relevant members of human DYRK kinases (DYRK1A, DYRK1B and DYRK2) in 
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the presence of the proteasome inhibitor MG-132 to avoid SIAH2 auto-degradation. As 
shown in figure 13A, DYRK1B and DYRK2 overexpression resulted in the appearance 
of several slower migrating SIAH2 bands, an effect not observed with DYRK1A. Similar 
results were obtained when SIAH2 phosphorylation was scored with an antibody 
specifically recognizing SIAH2 phosphorylation at Ser28 (Calzado et al, 2009), as 
DYRK2 caused the strongest signal. To test whether the upshifted SIAH2 band 
represents the phosphorylated form of the E3 ligase, cell extracts were incubated with 
λ phosphatase and analyzed for their electrophoretic mobility by Western blotting. 
Treatment with λ phosphatase converted the slower electrophoretic mobility of SIAH2 
back to that of the faster migrating bands as they occur upon expression of SIAH2 
alone (Figure 13B), indicating that DYRK2-mediated SIAH2 phosphorylation can be 
revealed by the differential electrophoretic mobility of SIAH2 bands. 
 
 
 
Figure 13. DYRK2 phosphorylates SIAH2. A. 293T cells were transfected with the indicated 
plasmids and 36 h later cells were treated with 10 μM MG-132 for 12 h before lysis. Protein 
expression was evaluated by immunoblot with the indicated antibodies and SIAH2 
phosphorylation studied with a specific antibody against SIAH2 phospho-Ser28. B. Cells were 
transfected with the indicated combinations of plasmids and treated with MG-132 for 12 h. The 
sample was lyzed in phosphatase inhibitor-free buffer containing λ phosphatase as shown and 
the electrophoretic mobility of SIAH2 determined by immunoblotting. 
  
 The upshifted SIAH2 form only occurred upon expression of the wildtype 
kinase, while a DYRK2 kinase dead mutant did not cause any alterations in the 
electrophoretic mobility of SIAH2 (Figure 14A). The relevance of the DYRK2 kinase 
activity for SIAH2 was underscored by experiments where increasing amounts of 
Harmine, a natural compound able to inhibit DYRK2 activity (Bain et al, 2007), caused 
a clear decrease in the bands with a slower mobility as well as SIAH2 phosphorylation 
at Ser28 (Figure 14B). 
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Figure 14. DYRK2 phosphorylates SIAH2. A. 293T cells expressing Flag-tagged SIAH2 and 
wild-type or kinase-inactive HA–DYRK2 KD were grown in the presence of MG-132. Cell lysates 
were analyzed by immunoblotting. B. Flag-SIAH2 was expressed either alone or along with 
DYRK2 in the presence of MG-132 and incubated with 2,5 and 5 μM of Harmine during 12 h 
before lysis. SIAH2 was analyzed for its electrophoretic mobility by immunoblotting and the 
phosphorylation level studied with a specific antibody against SIAH2 phospho-Ser28. 
  
 To study whether DYRK2 is directly mediating SIAH2 phosphorylation, we 
performed an in vitro kinase assay with purified recombinant proteins GST fusion 
proteins. GST-DYRK2 caused the phosphorylation of GST-SIAH2, as revealed by 
immunoblotting with a specific phosphoserine antibody (Figure 15A). To study the 
function of DYRK2 for phosphorylation of the endogenous SIAH2 protein, 293T cells 
were transfected with a specific DYRK2 siRNA, followed by the analysis of SIAH2 
Ser28 phosphorylation with specific antibodies. The inhibition of DYRK2 expression 
resulted in decreased constitutive SIAH2 Ser28 phosphorylation (Figure 15B), thus 
revealing the physiological importance of DYRK2 for SIAH2 phosphorylation. 
Collectively, these experiments identify DYRK2 as a kinase with the ability to directly 
phosphorylate SIAH2. 
 
6. DYRK2 phosphorylates SIAH2 in at least five residues 
 To identify the putative SIAH2 sites phosphorylated by DYRK2, we mutated 
proline-flanked serines and threonines to alanine. Coexpression of the mutants with 
DYRK2 and subsequent analysis of their electrophoretic behaviour showed that 
mutation of Thr26, Ser28 and Ser68 resulted in increased electrophoretic mobility 
(Figure 16A). A SIAH2 mutant with mutations in all three residues (SIAH2-3A) was still 
upshifted by DYRK2 (Figure 16B), indicating the existence of further phosphorylation 
sites. 
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Figure 15. DYRK2 phosphorylates SIAH2. A. In vitro Kinase assay was employed with 
bacterially purified GST-SIAH2 and commercial recombinant DYRK2 protein. SIAH2 
phosphorylation was evaluated by immunoblot with anti-phosho serine antibody. Protein levels 
were visualized by coomassie staining. B. Endogenous levels of phospho SIAH2 were analyzed 
by western blot using a specific antibody against SIAH2 phospho Ser28. DYRK2 protein was 
immunoprecipitated using a specific antibody and its expression evaluated by immunoblot.  
 
 
 
Figure 16. DYRK2 phosphorylates SIAH2. A. 293T cells were transfected with the indicated 
plasmids and treated 12 h before lysis with 10 μM of MG-132. Electrophoretic mobility shift of 
different SIAH2 phospho mutants was analyzed by immunoblotting. B. 293T cells transiently 
transfected with Flag-SIAH2 or 3A mutant (T26A, S28A and S68A) were grown in the presence 
of 10 μM MG-132. SIAH2 and -3A electrophoretic mobilities were analyzed by immunoblotting. 
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 To identify the phosphorylation sites by an unbiased approach, SIAH2 was 
coexpressed either alone or together with DYRK2, followed by isolation of the E3 ligase 
via immunoprecipitation and analysis by mass spectrometry. We were able to achieve 
protein coverage up to 64% (Figure 17A). Phosphorylation site analysis confirmed the 
three phosphorylated residues described above and also allowed the identification of 
Ser16 and Thr119 as new phosphorylation sites (Figure 17B). Mutation of the five 
residues (SIAH2-5A) significantly decreased SIAH2 migration (compare first and last 
lanes), although the slight remaining upshift may harbor further phosphorylation sites 
contained in sequences not covered by the mass spectrometry analysis (Figure 17C). 
 
 
Figure 17. DYRK2 phosphorylates SIAH2 in at least five residues. A. SIAH2 full length 
protein sequence. Underlying text show the SIAH2 sequence covered by tandem mass 
spectrometry analysis. In bold are show the amino acids phosphorylated identified in this study. 
B. Schematic representation of SIAH2 structure showing the phosphorylated residues revealed 
by Mass Spectrometry analyses. (C) 293T cells expressing the indicated SIAH2 point mutants 
together with DYRK2 were treated during 12 h with MG-132. Cell lysates were analysed by 
immunoblotting. 
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 To study DYRK2-mediated phosphorylation the individual SIAH2 sites we 
generated phosphospecific antibodies against each phosphorylated SIAH2 residue. 
While we successfully raised highly specific antibodies for most of the phosphorylation 
sites we failed to produce Ser16-specific antibodies. DYRK2 can function as a priming 
kinase for substrates such as c-Jun and c-Myc (Taira et al), raising the possibility that 
phosphorylation at specific residues is the prerequisite for phosphorylation at other 
sites. To test this, SIAH2 and phosphorylation site mutants were expressed alone or 
together with DYRK2, followed by detection of single site phosphorylation with the 
phospho-specific antibodies (Figure 18). DYRK expression caused phosphorylation at 
all sites, while Ser28 mutation precluded also phosphorylation at the neighboring 
Thr26.  
 
Figure 18. Influence of phophorylation in phospho-SIAH2 mutants. Flag-SIAH2 or the 
different SIAH2 point mutants were expressed either alone or along with DYRK2 in 293T cells in 
the presence of MG-132. SIAH2 was analyzed for its electrophoretic mobility by immunoblotting 
and the phosphorylation level studied with the indicated specific antibodies. 
 
 As these sites are closely adjacent and also Ser28 will be part of the epitope 
recognized by the phospho-Thr26 antibody, we do not consider Ser28 as a priming 
phosphorylation site. Ser68 showed highly phosphorylated in basal conditions as 
compared to the others residues. We did not observe any significant changes in the 
phosphorylation of the different residues in response to points mutations, which 
probably indicate that at least in the case of DYRK2 no clear phosphorylation hierarchy 
exists. Taken together, all these results clearly indicate that DYRK2 can specifically 
phosphorylate SIAH2 at minimal five residues. 
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7. SIAH2 colocalizes and interacts with DYRK2 
 To study the subcellular localization of both proteins by indirect 
immunofluorescence, U2OS cells were stained for endogenous DYRK2 and for 
ectopically expressed SIAH2, as the detection of the endogenous E3 ligase is 
precluded by low protein levels and the limited quality of available antibodies. Confocal 
microscopy showed that the Flag-tagged SIAH2 protein (mutated in the RING domain 
to avoid its self-degradation) and endogenous DYRK2 mainly colocalize in the 
cytoplasm and partially in the nucleus (Figure 19). Correlation analysis revealed a 
value of 0.79 ± 0.06 for Pearson’s coefficient indicating a high degree of colocalization 
between SIAH2 and DYRK2. 
 
Figure 19. SIAH2 colocalizes with DYRK2. U2OS cells were transfected with Flag-SIAH2 RM 
and analyzed for SIAH2 and endogenous DYRK2 localization by indirect immunofluorescence. 
Overlapping localization in merged pictures is shown in yellow. Nuclear DNA was stained with 
DAPI. Scale bar = 10 μM. 
 
 To assess whether SIAH2 interacts with endogenous DYRK2, we expressed 
Flag-SIAH2 in 293T cells and performed co-immunoprecipitation assays. Endogenous 
DYRK2 co-immunoprecipitated efficiently with SIAH2. Similarly, endogenous SIAH2 
also co-immunoprecipitated with DYRK2, thus confirming the existence of DYRK2-
SIAH2 complex under physiological conditions (Figure 20A). To test whether the 
interaction between SIAH2 and DYRK2 is direct and to characterize the responsible 
domain, we performed GST-pulldown assays (Figure 20B). Flag-tagged DYRK2 was 
efficiently captured by full-length SIAH2, but also by mutants lacking parts of the N- and 
C-terminus, suggesting the existence of more than one SIAH2 domain responsible for 
binding to DYRK2. 
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Figure 20. SIAH2 interacts in vivo and in vitro with DYRK2. A. 293T cells were transfected 
with Flag-SIAH2 or Flag-DYRK2 and treated with 10 μM of MG-132 during 12 h before lysis. A 
fraction was subjected to immunoprecipitation (IP) using anti-Flag antibody. After elution, 
DYRK2 or SIAH2 proteins were detected by western blotting with antibodies specific for DYRK2 
and SIAH2. The remaining extract fraction was tested for the occurrence of the indicated 
proteins by immunoblotting (INPUT). B. GST pull down assay was carried out incubating soluble 
GST-SIAH2 or deleted versions ΔN (117-324) and ΔC (1-116) with 293T cell extracts 
expressing Flag-DYRK2. DYRK2 bounded proteins were detected by immunoblotting with anti-
Flag antibody. A fraction of the cell extracts used and the Coomassie-stained display the input 
material. 
 
 To characterize SIAH2 interaction sites with DYRK2 in detail we performed a 
peptide array experiment. This technique has been widely used to define sites of direct 
interaction on many proteins including SIAH2 (Le Moan et al). A peptide library 
consisting of overlapping fragments representing the entire SIAH2 protein was 
incubated with GST-DYRK2 or the GST. Detection of the bound material by antibodies 
showed that DYRK2 binds two distinct domains of SIAH2: the N-terminal domain (aa 1-
28, peptides 1-9) and an area comprising the first zinc finger domain (aa 119-150, 
peptides 60-70) present in the substrate-binding domain (SBD) (Figure 21). Overall, 
these results prove the direct interaction between DYRK2 and SIAH2 as well as the 
possible relevant role of the first zinc finger domain present in the substrate-binding 
domain of SIAH2. 
 
8. SIAH2 mediates DYRK2 ubiquitination 
 As SIAH2 leads to ubiquitination and degradation of many of its interaction 
partners we tested the impact of SIAH2 expression at different optimum levels on the 
endogenous DYRK2. Expression of increasing amounts of SIAH2 resulted in a dose-
dependent decrease of DYRK2 protein levels. While the protein levels decreased, the 
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mRNA levels of DYRK2 were not significantly changed, as revealed by qPCR (Figure 
22A). A comparative analysis of SIAH1 and SIAH2 showed that SIAH2 was much more 
efficient in its ability to trigger DYRK2 degradation (Figure 22B). 
 
 
Figure 21. Peptide array assay. (Upper panel) Schematic diagram of peptide array binding 
assay. Peptide array library covering the complete sequence of SIAH2 was screened with 
recombinant GST-DYRK2 protein or GST protein for control. Recombinant GST-DYRK2 
revealed two distinct domains of interaction with SIAH2 (shown in box): N-terminal domain (aa 
1-28, peptides 1-9) and an area comprising the first zinc finger domain (aa 119-150, peptides 
60-70). (Lower panel) Sequences of SIAH2 peptides interacting with DYRK2. 
 
To assess whether SIAH2 can degrade DYRK2 through an 
ubiquitin/proteasome-dependent process, increasing amounts of SIAH2 were 
coexpressed with DYRK2 in the presence or absence of MG-132. The addition 
of this proteasome inhibitor prevented DYRK2 degradation and also stabilized 
the SIAH2 protein (Figure 23A). Along this line, the expression of ligase-
deficient SIAH2 point mutant (SIAH2 RM) failed to cause DYRK2 degradation 
(Figure 23B). This degradation is specific for DYRK2, as expression of either 
SIAH1 or SIAH2 could not change the protein levels of the DYRK family 
members DYRK1A or DYRK1B (Figure 23C). All these data show that SIAH2-
mediated DYRK2 degradation is performed by the proteasome, depends on 
SIAH2 ligase activity and is DYRK2-specific. 
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Figure 22. SIAH regulates DYRK2 at a protein level. A. 293T cells were transfected with the 
indicated plasmids. Endogenous DYRK2 protein level and relative mRNA expression was 
analyzed in response to increasing concentration of SIAH2. For real-time analysis β-actin gen 
was used for normalization. Data are mean ± S.D. of n = 3. B. 293T cells were transfected with 
HA-DYRK2 and an increasing concentration of Flag-SIAH1 or Flag-SIAH2. Cells extracts were 
subjected to western blot and revealed with the indicated antibodies. 
 
 To assess whether SIAH2 can degrade DYRK2 through an 
ubiquitin/proteasome-dependent process, increasing amounts of SIAH2 were 
coexpressed with DYRK2 in the presence or absence of MG-132. The addition of this 
proteasome inhibitor prevented DYRK2 degradation and also stabilized the SIAH2 
protein (Figure 23A). Along this line, the expression of ligase-deficient SIAH2 point 
mutant (SIAH2 RM) failed to cause DYRK2 degradation (Figure 23B). This degradation 
is specific for DYRK2, as expression of either SIAH1 or SIAH2 could not change the 
protein levels of the DYRK family members DYRK1A or DYRK1B (Figure 23C). All 
these data show that SIAH2-mediated DYRK2 degradation is performed by the 
proteasome, depends on SIAH2 ligase activity and is DYRK2-specific.  
To test whether SIAH2 mediates DYRK2 ubiquitination in vivo, we co-expressed 
His-Ubiquitin and Flag-DYRK2 with or without different concentrations of SIAH2 in the 
presence of MG-132. Then we pulled down His-Ubiquitin from cell lysates under 
denaturing conditions using Ni-NTA beads and analysed the ubiquitination status of 
DYRK2 by immunoblotting. These experiments showed that SIAH2 strongly stimulated 
basal DYRK2 polyubiquitination (Figure 24), thus identifying DYRK2 as a bona fide 
target for SIAH2. 
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Figure 23. SIAH2 catalyzes DYRK2 degradation through the proteasome. A. Cells 
transfected to express Flag-DYRK2 and increasing amounts of SIAH2 were grown in the 
presence or absence of MG-132. Cell lysates were analyzed by immunoblot with the indicated 
antibodies. B. 293T cells were transfected with the indicated plasmids and DYRK2 protein 
levels were evaluated by immunoblot in response to increasing concentration of SIAH2 wild type 
or SIAH2 ring mutant (RM). (C) Cells were transfected to express Flag-DYRK1A, Flag-DYRK1B 
and Flag-DYRK2 in the presence of HA-SIAH1 or HA-SIAH2. Cells were further grown, lysed 
and the protein expression analyzed by immunoblot with the indicated antibodies. 
 
9. SIAH2 controls DYRK2 expression in response to hypoxia 
   
 As SIAH2 is an important regulator of the hypoxic response, it was interesting to 
test whether SIAH2 has the ability to regulate DYRK2 expression levels in response to 
low oxygen levels. Cells expressing low levels of DYRK2 were subjected to hypoxia 
(1% O2) for different periods and subsequently analyzed by immunoblotting for the 
occurrence of the kinase. Hypoxia caused DYRK2 degradation in a time-dependent 
manner (Figure 25A). Treatment with MG-132 prevented hypoxia-mediated DYRK2 
degradation and also stabilized the kinase under normoxic conditions (Figure 25B).  
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Figure 24. SIAH2 mediates DYRK2 ubiquitination. Cells were transfected with Flag-DYRK2, 
His-tagged ubiquitin and increasing amounts of SIAH2. A fraction was tested for the occurrence 
of the indicated proteins by immunoblotting (INPUT). Another aliquot was lysed under 
denaturing conditions, followed by purification of His-tagged ubiquitin on Ni-NTA agarose 
columns and detection of ubiquitylated DYRK2 by immunoblotting. 
 
 
 
 
Figure 25. Hypoxia regulates DYRK2 levels. A. 293T cells expressing Flag-DYRK2 were 
grown in normoxia or hypoxia (1% O2) for the indicated times and DYRK2 expression was 
analyzed by immunoblotting. B. 293T cells were incubated under normoxic or hypoxic (12 h) 
conditions in the presence of 10 μM of MG-132 as shown, and analyzed by immunoblotting with 
an anti-DYRK2 antibody. 
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 To demonstrate the contribution of SIAH2 to this process, hypoxia-mediated 
DYRK2 decay was compared between control cells and cells where endogenous 
SIAH2 was knocked down by siRNA treatment. These experiments showed that 
hypoxia-mediated DYRK2 degradation only occurred in the presence of SIAH2 (Figure 
26). SIAH2 depletion also increased DYRK2 levels under normoxic conditions, 
indicating that both basal and SIAH2-mediated ubiquitin/proteasome-dependent 
DYRK2 degradation also occurs in well-oxygenated cells. 
 
Figure 26. DYRK2 expression is regulated by SIAH2 on hypoxia. 293T cells were 
transfected with 100 nM of scrambled (control) or SIAH2 siRNA. After 4 days, cells were 
cultivated under normoxic or hypoxic conditions and analyzed for DYRK2 and SIAH2 as shown. 
  
 Next we were interested in determining the phosphorylation state of the 
endogenous SIAH2 protein under normoxic and hypoxic conditions as compared to 
DYRK2 endogenous protein levels. 293T cells were treated with or without MG-132, 
and SIAH2 phosphorylation endogenous levels analysed in hypoxia and normoxia 
(Figure 27A). Hypoxia-mediated DYRK2 decrease was accompanied by a clear 
reduction in endogenous SIAH2 basal phosphorylation. Treatment with MG-132 caused 
the accumulation of DYRK2 endogenous levels, which were accompanied by a very 
significant increase in SIAH2 phosphorylation. Hypoxic conditions also resulted in 
diminished SIAH2 phosphorylation when the phosphorylation was triggered by DYRK2 
expression (Figure 27B). 
The effect of hypoxia on ubiquitination of DYRK2 in vivo was tested in cells that 
were cotransfected to express low amounts of His-Ubiquitin and Flag-DYRK2. These 
cells were incubated in the presence of MG-132 for various periods under hypoxic 
conditions. After purification of ubiquitinated proteins under denaturing conditions by Ni-
NTA pull-down the ubiquitination status of DYRK2 was analyzed by Western blotting. 
These experiments showed a clear increase in DYRK2 polyubiquitination in response 
to low O2 concentrations (Figure 28). 
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Figure 27. DYRK2 expression is regulated by SIAH2 on hypoxia. A. Cells were grown under 
normoxic or hypoxic conditions as shown, in the presence or absence of MG-132. Immunoblot 
analysis of endogenous DYRK2 and phospho SIAH2 was employed using anti-DYRK2 and a 
specific antibody against SIAH2 phosphorilated Ser28. B. 293T cells expressing Flag-DYRK2 
were grown in normoxia or hypoxia (1% O2) 12 h before lysis. Endogenous levels of phospho-
SIAH2 were analyzed by immunoblotting with a specific antibody against SIAH2 Ser28 
phosphorilated. 
 
 
 
  
 
 
Figure 28. Hypoxia regulates DYRK2 ubiquitination. Cells were transfected with Flag-
DYRK2, His-tagged ubiquitin and were grown in normoxia or hypoxia (1% O2) for the indicated 
times in the presence of MG-132. A fraction was tested for the occurrence of DYRK2 by 
immunoblotting (INPUT). Another aliquot was lysed under denaturing conditions, followed by 
purification of His-tagged ubiquitin on Ni-NTA agarose columns and detection of ubiquitylated 
DYRK2 by immunoblotting. 
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 To test the functional consequences of DYRK2 degradation by SIAH2, we 
studied whether SIAH2 expression affected DYRK2 ability to phosphorylate p53. U2OS 
cells were exposed to genotoxic damage by Doxorubicin and subjected to hypoxia 
conditions (Figure 29). DYRK2 inhibition in response to hypoxia caused a clear delay 
and decrease in p53 phosphorylation in Ser46 (Upper panel). The residual 
phosphorylation is probably due other kinases such as ATM, PKCδ, AMPKα or p38 
which target the same site (Smeenk et al, 2011). As p53 phosphorylation at Ser46 
triggers its ability to induce the transcription of proapoptotic genes, it was interesting to 
investigate the effect of DYRK2 and SIAH2 on the transcriptional activity of p53. H1299 
cells deficient for p53 were transfected with a p53-inducible luciferase reporter 
construct (p53-Luc) together with p53 and various combinations of the p53 kinase 
DYRK2 and SIAH2. Luciferase assays showed that p53-induced transcription was 
further boosted by DYRK2, while coexpression of SIAH2 antagonized this stimulatory 
effect. Very similar results were obtained with another reporter gene consisting of the 
p53-dependent Bax promoter fused to the luciferase gene (Figure 23 lower pannel). 
 
Figure 29. SIAH2-dependent p53 regulation on hypoxia. (Upper panel) H1299 cells were 
treated with 2 μg/ml doxorubicin for the indicated times. After the addition of doxorubicin cells 
were further incubated for the indicated periods under normoxic or hypoxic conditions. Cell 
lysates were evaluated by immunoblot with the indicated antibodies. (Lower panel) H1299 cells 
were transfected with p53-Luc or Bax-Luc reporter plasmids together with expression plasmid 
for DYRK2, SIAH2 and p53 and luciferase activity analyzed. Data are means ± S.D of n=3 
experiments. 
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10. Phosphorylation of SIAH2 by DYRK2 affects its localization and ability to 
degrade PHD3 
 Is DYRK2-mediated phosphorylation of SIAH2 affecting its activity? To study the 
effect of SIAH2 phosphorylation on its ability to degrade DYRK2 we transfected 293T 
cells with an expression vector for HA-SIAH2 together with increasing amounts of Flag-
DYRK2 or the kinase inactive mutant Flag-DYRK2 KD. Immunoblotting revealed that 
DYRK2 was equally degraded by SIAH2 irrespective of the presence of its kinase 
activity (Figure 30A). A similar result was observed in DYRK2 degradation by hypoxia 
treatment (Figure 30B). To determine in detail the effect of SIAH2 phosphorylation on 
DYRK2, we compared the ability of the SIAH2-5A phosphorylation mutant and the 
SIAH2-5D phospho-mimic mutant (Ser16, Thr26, Ser28, Ser68 and Thr119 to Asp) to 
degrade DYRK2. 293T cells were transfected with DYRK2 together with Flag-SIAH2-
wt, Flag-SIAH2-5A and Flag-SIAH2-5D and DYRK2 expression was studied by 
immunoblotting (Figure 30C). Consistent with the previous experiments, DYRK2 was 
equally degraded by SIAH2 wild type compared with the SIAH2 mutants. Taken 
together, these results show that SIAH2 phosphorylation has no effects on its capacity 
to degrade DYRK2. 
 
  
Figure 30. SIAH2 phosphorylation has no effect upon DYRK2 stability. A. 293T cells were 
transfected with expression vectors encoding Flag-DYRK2 and Flag-DYRK2 kinase dead 
mutant with increasing concentration of HA-SIAH2. The next day cells were lyzed and the 
stability of DYRK2 was revealed by immunoblotting. B. 293T cells were transfected with Flag-
DYRK2 or Flag-DYRK2-KD (kinase death) and grown under normoxia or hypoxia (1% O2) for 
the indicated times before lysis. DYRK2 protein levels were analyzed by immunoblotting. C. 
293T cells were co-transfected with Flag-DYRK2 and an increasing concentration of Flag-
SIAH2 or mutants -5A, 5D. Cell lysates were evaluated by immunoblot with the indicated 
antibodies. 
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 Next we were interested in studying how SIAH2 phosphorylation affects its 
stability. To confirm this possibility 293T cells were transfected with Flag-SIAH2 or 
Flag-SIAH2-5A with or without HA-DYRK2 in the presence or absence of MG-132 
(Figure 31A). Both SIAH2 and SIAH2-5A mutants were able to degrade DYRK2 
equally, which reinforces the hypothesis that the phosphorylation state does not alter 
SIAH2 ability to degrade DYRK2. However, Flag-SIAH2-5A mutant showed much more 
stability than Flag-SIAH2-wt in the absence of MG-132. This indicates that SIAH2 
phosphorylation in these 5 sites can affect SIAH2 stability. To assess whether the 
stability change of SIAH2 could be due to an alteration in its activity, we compared 
SIAH2-wt self-ubiquitination activity to that of SIAH2-5A mutant. As shown in Figure 
31B, both of them showed a similar ubiquitination pattern, pointing that the 
phosphorylation state does not seem to affect SIAH2 ligase ubiquitin activity. 
 
 
Figure 31. Phosphorylated SIAH2 is less stable. A. Cells were transfected with expression 
vectors encoding HA-DYRK2 and limiting amounts of Flag tagged versions of SIAH2 or SIAH2-
5A with or without MG-132. Cell lysates were analysed by immunoblotting. B. 293T cells were 
transfected with expression vectors encoding HA-Ubiquitin, Flag-SIAH2 or Flag-SIAH-5A, and 
treated with MG-132 during 12 h before lysis. Cell lysates were analysed by immunoblotting. 
 
 To investigate the consequences of SIAH2 phosphorylation for its intracellular 
localization, HeLa cells were transfected with Flag-SIAH2, Flag-SIAH-5A and Flag-
SIAH2-5D and analyzed by immunofluorescence microscopy. SIAH2 wild type and 
SIAH2-5A showed a similar localization pattern and were found mainly in the nucleus 
Figure 19 
50 
37 
70 
Flag-SIAH2 
HA-DYRK2 
+ 
+ 
- - 
- 
+ - 
+ 
- 
+ 
+ - 
- 
- 
- 
+ 
+ 
- - 
- + 
- + + 
SIAH2 
Actin 
DYRK2 HA 
Flag 
Actin 
-SIAH2 P 
Flag-SIAH2-5A + 
- 
+ 
+ 
+ 
- 
- 
+ 
A B 
150 
75 
50 
35 
150 
250 
75 
50 
35 
Flag 
SIAH2 
50 
Actin Actin 
Ubi*SIAH2 
Ubiquitin HA 
Flag-SIAH2 + + - - 
- - Flag-SIAH2-5A + + 
MG-132 + + + + 
- + - + HA-Ubiquitin 
Results 
 
49 
and partially in cytoplasm (Figure 32). In contrast, the phosphomimic mutant showed a 
decrease in its nuclear localization which was paralleled by an increased localization in 
the perinuclear region. These results suggest that SIAH2 phosphorylation state can 
affect its stability, without affecting its self-ubiquitination activity probably because of a 
change in its subcellular localization. 
 
  
Figure 32. Phosphorylated SIAH2 locates differently. U2OS cells expressing the indicate 
plasmids were treated with MG-132, fixed and SIAH2 wild type, SIAH2-5A, and SIAH2-5D were 
detected by indirect immunofluorescence microscopy. Nuclear DNA (blue) was stained with 
DAPI. 
 While the phosphorylation state of SIAH2 had no impact on DYRK2 it was 
interesting to investigate possible effects for other SIAH2 substrates. Thus we 
examined the effect of the SIAH2 phosphorylation state on its ability to degrade PHD3, 
one of the most relevant SIAH2 substrates and a key protein in the hypoxia response 
pathway. Cells were transfected with PHD3 together with different SIAH2 variants and 
a luciferase construct controlled by the HIF-1-dependent erythropoietin promoter (Epo-
Luc) as indicated (Figure 33). SIAH2 expression produced a clear decrease in PHD3 
expression, which was reflected in a significant increase of HIF-dependent Epo-Luc 
promoter activity. The SIAH2-5A phosphorylation mutant showed a reduced ability to 
degrade PHD3 (compare lanes 3 and 2), which was reflected in a lower response to 
Epo-Luc promoter. In contrast, the phospho-mimetic SIAH2-5D mutant showed a 
strongly increased ability to degrade PHD3 (compare lanes 4 and 1), which was also 
refelected by a further increase of the Epo-Luc promoter response. Similar results were 
observed when SIAH2 phosphorylation was triggered upon co-expression of DYRK2. 
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These data suggest that SIAH2 phosphorylation state can modulate its ability to 
degrade PHD3. 
 
 
Figure 33. Phosphorylation of SIAH2 by DYRK2 affects its ability to degrade PHD3. Cells 
were transfected with the indicated expression vectors together with an HIF-responsive, 
erythropoietin promoter-derived luciferase construct (Epo-Luc). An empty expression vector was 
included for normalization of the transfections. Two days later, cells were cultured and analysed 
for luciferase expression (upper panel) or by immunoblotting (lower panel). Data are means ± 
S.D of n=3 experiments. 
 
 To test the functional consequences of SIAH2 phosphorylation on the hypoxia 
response pathway in a physiological model, we measured endothelial cell tube 
formation as a model of angiogenesis. HUVEC cells were transfected with the different 
SIAH2 variants and tubule formation was quantified using a BD PathwayTM Bioimager 
(Figure 34). SIAH2 expression resulted in an increased tube total length and tube 
branch points. The tubular structures in HUVEC transfected with the SIAH-5A mutant 
were significantly (tubes total length P<0.05, tubes branch points P<0.01) shorter than 
those transfected with SIAH2 wild type. On the other hand, SIAH2-5D expression 
resulted in an increased number of tubular structures, strongly corroborating the finding 
that phosphorylated SIAH2 has an augmented ability to trigger the hypoxic response. 
These results identify the phosphorylation state of SIAH2 as a critical step in the control 
of the hypoxia response pathway, which has a clear consequence on angiogenesis. 
On the whole these results emphasize the use of NADA, SIAH2 and 
DYRK2 as potential targets of therapeutic intervention for advanced cancers, 
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which may be achieved by restoring and inhibiting DYRK2 and SIAH2 
expression and function, respectively. 
 
 
Figure 34. Enhanced down-regulation of PHD3 in the presence of phosphorylated SIAH2. 
HUVEC cells were transfected with expression vectors encoding Flag-SIAH2 and the variant 
mutants Flag-SIAH2-5A and Flag-SIAH2-5D two days prior to plating on Matrigel-coated culture 
dishes. Quantitative analysis of tube formation was performed in a BD Pathway 855 Bioimager 
using Attovission v 1.7 BD software. Protein levels were analysed by inmunoblot. Three 
independent experiments were performed. Data are means ± S.D of n=3 experiments. 
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Discussion 
 The metabolism of the arachidonic acid by cyclooxygenases plays an important 
role both in physiological and pathological events in the CNS (Hewett et al, 2006). At 
the CNS level it has been demonstrated that the hippocampus and the striatum are the 
regions of the brain containing higher concentrations of NADA (Huang et al, 2002). 
Thus, the cells in these regions may also have a biosynthetic pathway of N-acyl-
dopamines similar to the cells of the carotid body and under pro-inflammatory 
conditions CNS cells could release NADA in the brain and induce not only activities 
inherent to the activation of TRPV1 and CB1 receptors but also neuroprotective 
activities. 
 Like many genes coding for mRNA short half-life (i.e. cytokines), the COX-2 
gene also contains ARE sequences (composed by six elements AUUUA), which 
regulate the stability of mRNA within the 30-UTR region. Previous studies have shown 
that ARE sequences present in the 30-UTR of COX-2 gene are responsible for the 
mRNA stabilization (Cok & Morrison, 2001; Dixon et al, 2000; Lasa et al, 2000). Our 
results indicate that NADA, and probably other N-acyl-dopamines, increase the half-life 
of the COX-2 mRNA in microvascular endothelial cells and this mechanism is 
dependent on the activation of p38. In other cell models it has been demonstrated that 
the activation of p38 allows the activation of MAPKAPK-2, which in turn activates a 
heat shock protein 27 (HSP27). This HSP27 has been implicated in the stabilization of 
COX-2 mRNA and, therefore, it is very likely that the final mechanism by which NADA 
induces the stabilization of COX-2 is due to activation of HSP27. All these results 
clearly show a potential role for NADA at the CNS highlighting the potential of 
endocannabinoids and N-acyldopamines as therapeutic agents for the treatment of 
inflammatory diseases and neuroprotection. 
As well as NADA, HIF-1α involvement in neuroprotection drove us to test the 
relationship between them. Our results show for the first time the effect of NADA on 
HIF-1α levels. Furthermore, since SIAH2 is a protein at the apex of the hypoxia 
response that rises the transcription factor HIF-1α we tested the possibility that NADA 
could modulate HIF-1α by means of a primarily down-regulation of SIAH2. In short, we 
found that NADA mediates SIAH2 down-regulation with clear outcomes in HIF-1α 
levels. 
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 The relation between SIAH2 and tumourigenesis has been widely described in 
the literature (House et al, 2009; Telerman & Amson, 2009). The role of this ubiquitin 
ligase as an expression modulator of the pro-angiogenic transcription factor HIF-1α, 
has brought an interest in the development of mechanisms able to regulate its 
expression (Qi et al, 2010; Qi et al, 2008). Different approaches have shown promising 
results, underlining the importance that SIAH2 modulation can exert on hypoxia-
mediated angiogenesis (Ahmed et al, 2008; Moller et al, 2009; Schmidt et al, 2007). A 
recent study performed on Siah2-/- mice has demonstrated how this protein attenuates 
HIF1α-mediated angiogenesis improving responses to chemotherapy, showing once 
more the importance of this upstream regulator of hypoxia (Wong et al, 2012). Thus 
SIAH inhibition would decrease the response of different tumourigenic pathways such 
as DNA damage signalling networks (Calzado et al, 2009; Matsuzawa & Reed, 2001), 
Ras pathway (Ahmed et al, 2008; Schmidt et al, 2007) and estrogen receptors (Jansen 
et al, 2009). In this dissertation we have shown a new way whereby the 
endocannabinoid NADA down-regulates SIAH2 levels. 
 The regulation of ubiquitin ligases is essential for the control of substrate 
expression. Although different common regulatory mechanisms for E3 ligases, such as 
deubiquitinating and sumoylation, have been described, little is known about the role of 
phosphorylation on ubiquitin ligases (de Bie & Ciechanover, 2011; Lipkowitz & 
Weissman, 2011). Others and we have shown that SIAH2 can be phosphorylated 
affecting its activity. To our knowledge, only two kinases have been described: HIPK2 
in human SIAH2 and p38 in mice (Calzado et al, 2009; Khurana et al, 2006). In this 
context, the present study shows for the first time the ability of DYRK2 to interact and 
phosphorylate human SIAH2 in at least five residues (Ser16, Thr26, Ser28, Ser68 and 
Thr119), two of which have not been described before. This ability of DYRK2 to interact 
with an E3 ubiquitin ligase coincides with recent studies that seem to demonstrate a 
possible role of this kinase in protein proteolysis (Maddika & Chen, 2009; Varjosalo et 
al, 2008). In this study we also show that SIAH2 phosphorylation state affects its 
activity, increasing PHD3 degradation and consequently HIF-1α levels, possibly due to 
a change in cell localization. These results are consistent with previous reports 
describing how SIAH1/2 phosphorylation is able to modulate its activity on certain 
substrates (House et al, 2009; Winter et al, 2008). We have also observed how this 
control of the hypoxia response pathway has a consequence on angiogenesis 
development. In this sense, although there are reports showing the relation between 
SIAH2 expression and tumourigenesis, the role of SIAH2 phosphorylation has not been 
Discussion!
!
55!
investigated previously. It will therefore be relevant to investigate potential changes of 
SIAH2 phosphorylation and its regulating events in physiological and 
pathophysiological settings in the future. 
 On the other hand, our findings also show that SIAH2 is able to regulate DYRK2 
expression by an ubiquitination mechanism that is enhanced under hypoxia conditions. 
Protein kinases are important for all fundamental processes and thus their activities 
must be tightly controlled, as unrestrained kinase activities as they occur for example in 
the oncogenic mutant versions of Raf-1 or Src kinases can lead to tumor development 
(Mansour et al, 1994). Cis-autophosphorylation of DYRK2 results in a constitutively 
active kinase that needs no additional activation signals from upstream kinases 
(Lochhead et al, 2005), thus raising the need to control DYRK2 activities by other 
mechanisms. These include DNA damage-induced nuclear translocation (Taira et al, 
2007) and ubiquitin/proteasome-mediated control of its protein stability. Accordingly, 
DYRK2 levels are kept low by constant ubiquitination that can be mediated by Mdm2 
(Taira et al, 2010) and also by SIAH2, as revealed in this study. The relative 
contribution of both E3 ligases for the steady-state-levels of DYRK2 are currently not 
known, but the strong upregulation of DYRK2 protein levels in the presence of a 
SIAH2-specific siRNA point to an important role of SIAH2. 
 Although DYRK2 functional role is not well known, recent publications by 
Yoshida K. group have risen the interest on this kinase and its modulation due to its 
relevant role on tumour progression control. First, DYRK2 exerts an important role on 
the regulation of the p53 tumour suppressor through its phosphorylation on Ser46, 
which is necessary for the induction of apoptosis in response to DNA damage (Taira et 
al, 2007). More recently, they have described the role exerted by DYRK2 on cell cycle 
progression through c-Jun and c-Myc phosphorylation, and how DYRK2 inactivation 
has a relevant role on proliferation and tumour progression (Taira et al, 2012). 
However, DYRK2 expression in human tumours is uncertain, and there is no 
concluding study about this subject. While mutations of DYRK2 are not often found in 
cancer cells, a deregulated expression was described by several groups. 
Overexpression of DYRK2 was reported in esophageal and lung adenocarcinomas 
(Miller et al, 2003), but on the other hand recent published data point at a reduced or 
abolished DYRK2 expression in multiple human tumour tissues, which correlates with 
invasiveness in the case of human breast cancer (Taira et al, 2012). Our data show 
that DNA damage-induced p53 Ser46 phosphorylation is strongly diminished under 
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hypoxic conditions, which is due to degradation of DYRK2 and probably also HIPK2, 
another p53-phosphorylating kinase that is downregulated under hypoxic conditions 
(Calzado et al, 2009). These mechanisms are of potential clinical relevance in solid 
tumors, as their central regions are typically hypoxic and thus show diminished p53 
phosphorylation and in addition these regions are not easily accessible for 
chemotherapeutic drugs. SIAH2 inhibition would increase HIPK2 and DYRK2 levels 
increasing cell sensibility to DNA damage induced apoptosis. 
 Taken together, our findings support a coordinated regulation model between 
SIAH2 and DYRK2 (Figure 35). On one hand, DYRK2 is able to phosphorylate SIAH2 
modifying its activity on relevant substrates as PHD3, modulating the hypoxia response 
pathway. On the other hand, SIAH2 is capable of interact and polyubiquitinate DYRK2 
promoting its degradation by the proteasome, and altering the p53-dependent 
apoptosis in response to DNA damage. Further research is needed to explain how this 
equilibrium is altered and which cell stimuli are necessary to tip the balance in favour of 
one or the other. 
 
Figure 35. Schematic model summarizing the coordinate regulation between SIAH2 and 
DYRK2. 
 
 In short, we have found that NADA activates a redox-sensitive p38 pathway that 
stabilizes COX-2 mRNA resulting in the accumulation of the COX-2 protein, which 
leads to regulation of inflammation, immunomodulation, blood flow, apoptosis and 
fever. As well as that, we have described a modulatory effect of NADA over SIAH2, 
which is widely described as a major ubiquitin ligase involved in tumorigenesis and 
hypoxia. In parallel with the latter effect, we show for the first time the ability of DYRK2 
to directly phosphorylate SIAH2 and, conversely, SIAH2-dependent DYRK2 
degradation. Finally, we reveal that such dual regulation has clear outcomes in both 
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PHD3 and p53 responses. These findings suggest new ways to target inflammation, 
tumorigenesis and apoptosis and urges further research to elucidate which stimuli, and 
under what circumstances, tip the balance to tumorigenesis or apoptosis.  
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CONCLUSIONS 
A number of conclusions can be drawn from this dissertation: 
1. NADA induces p38 MAPK phosphorylation which instigates COX-2 expression 
in brain endothelial cells. 
 
2. NADA-induced HIF-1α expression correlates with SIAH2. 
 
3. DYRK2 directly phosphorylates SIAH2 in five residues (S16, T26, S28, S68 and 
T119). 
 
4. SIAH2 phosphorylation by DYRK2 makes it less stable and more efficient to 
degrade PHD3. 
 
5. SIAH2 ubiquitinates DYRK2, which is degraded by the proteasome. 
 
6. DYRK2 degradation by SIAH2 in hypoxia have important effects on p53 Ser46 
phosphorylation. 
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1. Introduction
The past decade has seen a sudden spurt of interest in the
endocannabinoid system (ECs). This system regulates a plethora of
biological effects and is composed of cannabinoid and vanilloid
receptors, endogenous signaling molecules (called endocannabi-
noids) and metabolism-related enzymes [1,2]. Endocannabinoids
are a class of lipidmediators found in several tissues and based on a
polyunsaturated fatty acid amide or ester motifs [3]. Anandamide
(AEA) and 2-arachidonoylglycerol (2-AG) are the most character-
ized endocannabinoids acting in the brain and in peripheral tissues
mainly through the activation CB1 and CB2 cannabinoid receptors,
respectively. AEA can also interact with the vanilloid receptor type
1 TRPV1 [4,5]. This non-selective cation channel is activated by
vanilloids, such as capsaicin, and also by endogenous ligands N-
acyl-dopamines (neurolipins), such as N-arachidonoyl-dopamine
(NADA) and N-oleoyl-dopamine (OLDA) [6–8]. While NADA binds
TPRV1 [7,9], and CB1 receptor [10], OLDA is a capsaicin-like lipid
with full TPRV1 agonist activity but devoid of affinity for CB
receptors [8]. NADA induces several biological activities such as
hyperalgesia [8], smooth muscle contraction in the guinea pig
bronchi and bladder [11], vasorelaxation in blood vessels [12], and
also has immunomodulatory, neuroprotective and antiinflamma-
tory properties [13–15]. Their saturated analogs N-palmitoyl-
dopamine (PALDA) andN-stearoyl-dopamine (STEARDA)were also
identified as endogenous substances not activating TRPV1,
although they significantly enhanced the TRPV1-mediated effects
of NADA [8].
Endocannabinoids may play a major role in the central nervous
system (CNS), immune control and neuroprotection by regulating
the cellular network of communication between the nervous and
immune system during neuroinflammation and neuronal damage
[16–18]. In addition,N-acyl-dopamines influence the lipoxygenase
pathway of arachidonic acid cascade as substrates or inhibitors and
may also be involved in the regulation of inflammation [19,20].
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A B S T R A C T
Cerebral microvascular endothelial cells play an active role in maintaining cerebral blood flow,
microvascular tone and blood brain barrier (BBB) functions. Endogenous N-acyl-dopamines like N-
arachidonoyl-dopamine (NADA) and N-oleoyl-dopamine (OLDA) have been recently identified as a new
class of brain neurotransmitters sharing endocannabinoid and endovanilloid biological activities.
Endocannabinoids are released in response to pathogenic insults and may play an important role in
neuroprotection. In this studywe demonstrate that NADA differentially regulates the release of PGE2 and
PGD2 in the microvascular brain endothelial cell line, b.end5. We found that NADA activates a redox-
sensitive p38 MAPK pathway that stabilizes COX-2 mRNA resulting in the accumulation of the COX-2
protein, which depends on the dopamine moiety of the molecule and that is independent of CB1 and
TRPV1 activation. In addition, NADA inhibits the expression of mPGES-1 and the release of PGE2 and
upregulates the expression of L-PGD synthase enhancing PGD2 release. Hence, NADA and other
molecules of the same family might be included in the group of lipid mediators that could prevent the
BBB injury under inflammatory conditions and our findings provide new mechanistic insights into the
anti-inflammatory activities of NADA in the central nervous system and its potential to design novel
therapeutic strategies to manage neuroinflammatory diseases.
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